Purine nucleoside phosphorylase deficiency

Inborn Error of Metabolism MONDO:0013171 Pathograph 20 Show in embeddings browser Inborn disorder of purine metabolism Combined immunodeficiency Inborn error of metabolism

Purine nucleoside phosphorylase (PNP) deficiency is an autosomal recessive inborn error of the purine salvage pathway causing a combined immunodeficiency that falls predominantly on T cells, together with neurological disease and autoimmunity. It accounts for roughly 4% of severe combined immunodeficiency. The mechanism is a substrate-toxicity chain rather than a loss of product. PNP normally phosphorolyses inosine, guanosine and their deoxy forms; without it, deoxyguanosine accumulates and is phosphorylated to dGTP, a conversion that in the T-cell-lethal arm requires deoxycytidine kinase. PNP is expressed in most tissues but at its highest levels in lymphoid tissue, which is why an enzyme defect present in every cell produces a disease of the lymphoid system. Elevated dGTP is thought to inhibit ribonucleotide reductase and so impede cell division; a complementary and more specific mechanism, established in PNP-knockout mice, is that mitochondrial dGTP accumulation inhibits mitochondrial DNA repair, leaving T cells hypersensitive to spontaneous mitochondrial DNA damage and driving their depletion by apoptosis. Thymocytes and peripheral T cells die, thymic output fails, and combined immunodeficiency follows. Two features make this entry more than a metabolic chain. First, the neurological arm - spasticity, developmental delay, ataxia - is present in about two thirds of patients and is NOT explained by the T-cell mechanism; its basis remains genuinely unresolved and is curated as an open knowledge gap rather than asserted. Second, the disease has a demonstrated activity threshold: siblings with roughly 8-11% residual PNP activity reached their third decade with mild immune abnormalities and entirely normal neurological development, which sets a quantitative floor on how much enzyme is actually needed and is directly relevant to what any future enzyme- or gene-directed therapy must achieve.

Ask OpenScientist

Ask a research question about Purine nucleoside phosphorylase deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Part

👪

Inheritance

Autosomal recessive HP:0000007

Biallelic loss-of-function variants in PNP on chromosome 14q are required; carriers with one functional allele are unaffected, and the demonstration that 8-11% residual activity supports near-normal immunity explains why heterozygotes are healthy.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:30885031 SUPPORT Human Clinical

"Purine nucleoside phosphorylase (PNP) deficiency is a rare autosomal recessive primary immunodeficiency disorder characterized by decreased numbers of T-cells, variable B-cell abnormalities, decreased amount of serum uric acid and PNP enzyme activity."

States the autosomal recessive inheritance together with the defining immunological and biochemical features.

Discussions and Knowledge Gaps

What causes the neurological disease in PNP deficiency? About two thirds of patients have spasticity, developmental delay or intellectual disability, and about a quarter present neurologically rather than with infection, yet no established mechanism links the enzymatic defect to neuronal dysfunction. The only mechanistic proposal in the literature - that depressed GTP levels may correlate with neurologic dysfunction - is offered as a possible correlation rather than a demonstrated pathway.

KNOWLEDGE GAP OPEN pnp-neurological-mechanism

Attached to

pathophysiology#CNS Purine Nucleotide Imbalance pathophysiology#Neurological Dysfunction

Three observations make this a real gap rather than a missing citation. The neurological arm dissociates from the immunological one: patients are described with full immunodeficiency and autoimmunity but no neurological impairment. It is not corrected by the treatment that cures the immunodeficiency, since transplantation halts progression but does not reverse established disease. And the partial-deficiency siblings, with 8-11% residual activity, had entirely normal neurological development, which implies a threshold effect but says nothing about the mechanism below it. The clinical stake is direct: if the neurological injury is a prenatal or early-postnatal process, then newborn screening and very early transplantation would be the intervention, whereas if it is an ongoing metabolic toxicity then enzyme- or substrate-directed therapy able to cross the blood-brain barrier would be needed, since donor haematopoietic cells largely do not.

Proposed experiments

CSF purine profiling and neuroimaging across the PNP activity range

pnp-cns-purine-timing

Measure CSF purine nucleoside and nucleotide profiles alongside serial neuroimaging in patients spanning the full range of residual PNP activity, including pre- and post-transplant timepoints, to establish whether CNS purine imbalance tracks neurological severity, whether it is corrected by transplantation, and at what developmental stage the injury is established.

Readouts

CSF purine metabolite levels versus neurological severity and PNP activity

pathophysiology#CNS Purine Nucleotide Imbalance

Would support

pathophysiology#CNS Purine Nucleotide Imbalance pathophysiology#Neurological Dysfunction

Show evidence (2 references)

PMID:1931007 SUPPORT Human Clinical

"Depressed GTP levels may correlate with neurologic dysfunction."

The sole mechanistic proposal available, stated by the source itself only as a possible correlation - which is the gap.

PMID:32695102 SUPPORT Human Clinical

"All siblings had typical (normal) neurological development."

Partial deficiency with 8-11% residual activity spared neurological development entirely, establishing a threshold without explaining the mechanism operating below it.

The dual-checkpoint model - a SAMHD1-dependent synthetic lethality in developing T cells and a TLR7-ligand checkpoint in B cells and macrophages - elegantly explains why one metabolic gene produces both immunodeficiency and autoimmunity. It rests on mouse and cellular experiments. Do both checkpoints operate in human PNP deficiency, and does the TLR7 arm account for the autoimmunity seen in roughly a third of patients?

HUMAN MODEL MISMATCH OPEN pnp-dual-checkpoint-human-validation

Attached to

pathophysiology#Unrestrained TLR7 Signalling by Guanosine Nucleoside Ligands pathophysiology#SAMHD1-Dependent Synthetic Lethality in Developing T Cells

Evidence for this model exists and is mechanistically strong, so the open question is translational validity rather than absence of data - which is what makes this a HUMAN_MODEL_MISMATCH rather than a knowledge gap. It matters for two reasons. If the human autoimmunity is TLR7-driven, then TLR7-directed or nucleoside-lowering therapy is a rational adjunct in patients awaiting transplant, whereas conventional immunosuppression in a patient who is already immunodeficient is an unattractive option. And if the T-cell arm genuinely depends on deoxycytidine kinase and is antagonised by microenvironmental deoxycytidine, that is a pharmacologically approachable dependency rather than an inevitability of the enzyme defect.

Proposed experiments

TLR7 pathway activity in human PNP-deficient B cells and macrophages

pnp-human-tlr7-checkpoint

In patients with PNP deficiency, measure TLR7 pathway activation and interferon signatures in primary B cells and monocyte-derived macrophages, correlate with (deoxy)guanosine nucleoside levels and with the presence of autoimmune manifestations, and test whether ex vivo TLR7 blockade or nucleoside depletion normalises the signature.

Readouts

TLR7 pathway activation versus nucleoside levels and autoimmune status

pathophysiology#Unrestrained TLR7 Signalling by Guanosine Nucleoside Ligands

Would support

pathophysiology#Unrestrained TLR7 Signalling by Guanosine Nucleoside Ligands

Show evidence (2 references)

PMID:35653193 SUPPORT Model Organism

"PNP insufficiency in humans is paradoxically associated with both immunodeficiency and autoimmunity, but the mechanistic basis for these outcomes is incompletely understood."

The paper's own framing states that the human mechanistic basis is incompletely understood, which is precisely the mismatch this discussion records. Evidence source is MODEL_ORGANISM as the resolving experiments are murine and cellular.

PMID:35968787 SUPPORT Other

"In this issue of the JCI, Abt and colleagues report on purine nucleoside phosphorylase (PNP) deficiency, exploring the basis for the autoimmune complications that develop in this particular form of T cell immune deficiency and assigning a key role for overactivation of TLR7."

Independent commentary confirming the TLR7 attribution and its significance. Evidence source is OTHER as this is an editorial commentary rather than primary data.

⚙

Pathophysiology

Biallelic PNP Loss-of-Function Variants

Inheritance of two defective PNP alleles abolishes or severely reduces purine nucleoside phosphorylase activity in every cell. Because one functional allele suffices for health, and because as little as 8-11% of normal activity supports near-normal immunity and entirely normal neurological development, the disease requires near-complete enzyme loss rather than mere reduction.

Downstream

Loss of Purine Nucleoside Phosphorolysis Loss-of-function alleles remove the catalytic activity that this step depends on.

Show evidence (1 reference)

PMID:32695102 SUPPORT Human Clinical

"PNP activity in various cells from two patients were 8-11% of the normal level."

Establishes the residual-activity threshold: this level of activity was compatible with survival into the third decade and normal neurological development, so the severe disease requires near-complete loss.

Loss of Purine Nucleoside Phosphorolysis

PNP catalyses the phosphorolysis of inosine, guanosine, deoxyinosine and deoxyguanosine in the purine salvage pathway. Losing that step blocks the route from these nucleosides onward to hypoxanthine, xanthine and ultimately uric acid, and leaves the substrates to accumulate. The disease is therefore driven by what builds up behind the block rather than by any product the cell fails to make.

purine nucleoside catabolic process GO:0006152 ↓ DECREASED

purine-nucleoside phosphorylase activity GO:0004731 ⇓ LOSS OF FUNCTION

Downstream

Accumulation of Deoxyguanosine and Other PNP Substrates Blocking phosphorolysis causes the enzyme's own substrates to accumulate in cells and body fluids.

Hypouricemia and Elevated Urinary Purine Nucleosides With the catabolic route to uric acid interrupted, serum urate falls and unmetabolised nucleosides are excreted.

Show evidence (1 reference)

PMID:35063692 SUPPORT Human Clinical

"Purine nucleoside phosphorylase (PNP) is a key enzyme in the purine salvage pathway."

Places the lost enzymatic step in the purine salvage pathway, which is the content of this node.

Hypouricemia and Elevated Urinary Purine Nucleosides

Because uric acid is the end product of the interrupted pathway, serum urate is characteristically low - often strikingly so - and unmetabolised PNP substrates appear in the urine. This pairing is the cheap, widely available diagnostic clue that distinguishes PNP deficiency from other combined immunodeficiencies, and low uric acid in a lymphopenic infant should prompt the specific enzyme assay. Notably, urinary substrate elevation is the more sensitive of the two: partial-deficiency patients had entirely normal blood uric acid yet still excreted increased PNP substrates.

Show evidence (2 references)

PMID:33061764 SUPPORT Human Clinical

"Absolute lymphocyte counts and serum uric acid levels were very low, and serum immunoglobulin levels were normal or slightly lower in all cases."

Documents the low serum uric acid with lymphopenia in all four cases of a case series, the diagnostic signature this node represents.

PMID:32695102 SUPPORT Human Clinical

"All siblings had normal blood uric acid and increased PNP substrates in the urine."

Shows the two biochemical markers dissociate in partial deficiency - urate normal, urinary substrates raised. Recorded as PARTIAL because it supports the urinary marker while contradicting hypouricemia as a universal finding.

Accumulation of Deoxyguanosine and Other PNP Substrates

Inosine, guanosine, deoxyinosine and above all deoxyguanosine accumulate behind the enzymatic block. Deoxyguanosine is the toxic species: unlike the ribonucleosides it can be phosphorylated onward to a deoxynucleotide triphosphate, and it is this conversion that converts a metabolic block into cell death.

Downstream

Intracellular dGTP Pooling in Lymphoid Cells Accumulated deoxyguanosine is phosphorylated to dGTP, which is the proximate toxin; the T-cell-lethal arm of this conversion requires deoxycytidine kinase activity.

CNS Purine Nucleotide Imbalance Systemic purine imbalance extends to the central nervous system, but the intermediates linking it to neuronal dysfunction are not established - see the `pnp-neurological-mechanism` knowledge gap.

Unrestrained TLR7 Signalling by Guanosine Nucleoside Ligands The same accumulating (deoxy)guanosine nucleosides are ligands for TLR7, so the metabolic block simultaneously removes a brake on innate nucleic-acid sensing.

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"The elevated dGTP found in PNP deficiency is thought to inhibit ribonucleotide reductase and, thus, impede cell division."

Establishes deoxyguanosine-derived dGTP as the accumulating toxic species and names the classical downstream target.

Intracellular dGTP Pooling in Lymphoid Cells

Deoxyguanosine is phosphorylated to dGTP, which pools to toxic concentrations preferentially in lymphoid cells. The tissue selectivity is the crux of the disease and has a simple explanation: PNP is expressed in most tissues but at its highest levels in lymphoid tissue, so lymphoid cells carry the largest flux through the missing step and the largest substrate burden when it fails. This is why a ubiquitously expressed enzyme defect produces a predominantly lymphoid disease.

thymocyte CL:0000893 T cell CL:0000084

Animal models

B6-NPE / B6-NPF ENU-induced PNP-deficient mouse strains Mouse fails to recapitulate This is the honest negative result, and it is the structural counterpart of the HUMAN_MODEL_MISMATCH discussion. In the B6-NPE and B6-NPF PNP-deficient mouse lines, the dGTP accumulation that the whole human mechanism is built on was not detectable in thymocytes, spleen leucocytes or erythrocytes, and there were no changes in purine or pyrimidine ribonucleotide pools. The lines instead showed a secondary deficiency of deoxyguanosine kinase, which would prevent the toxic phosphorylation step from running - so the mouse partly protects itself from the very lesion the model is meant to represent.

Downstream

Ribonucleotide Reductase Inhibition and Impaired DNA Replication dGTP is an allosteric inhibitor of ribonucleotide reductase, distorting the deoxyribonucleotide pools required for DNA synthesis.

Mitochondrial dGTP Accumulation and Impaired mtDNA Repair dGTP accumulating in mitochondria inhibits mitochondrial DNA repair.

SAMHD1-Dependent Synthetic Lethality in Developing T Cells The synthetic-lethal interaction is not a standing property of the thymocyte but is created by the accumulating dNTP load: SAMHD1 is the triphosphohydrolase that would dispose of it, and developing thymocytes physiologically downregulate SAMHD1, so the dGTP burden arrives in the one cell type that has stood down its disposal capacity.

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"It is found in most tissues of the body but is at highest levels in lymphoid tissues. This tissue distribution explains why the lymphoid system is predominantly affected in PNP deficiency."

Supplies the explanation for the lymphoid selectivity that is the defining feature of this node.

Ribonucleotide Reductase Inhibition and Impaired DNA Replication

Elevated dGTP allosterically inhibits ribonucleotide reductase, the enzyme that supplies deoxyribonucleotides for DNA synthesis. The consequence is distorted dNTP pools and impeded cell division, which falls hardest on the rapidly proliferating thymocyte compartment. This is the classical explanation for the immunodeficiency and the direct mechanistic parallel with adenosine deaminase deficiency, where accumulated dATP acts on the same enzyme.

DNA replication GO:0006260 ↓ DECREASED

Downstream

Thymocyte and Peripheral T Lymphocyte Apoptosis Cells that cannot complete DNA replication in the proliferating thymocyte compartment die rather than mature.

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"The elevated dGTP found in PNP deficiency is thought to inhibit ribonucleotide reductase and, thus, impede cell division."

States the ribonucleotide reductase mechanism and its consequence for cell division, which is the content of this node. The hedged wording of the source is preserved in the node description.

Mitochondrial dGTP Accumulation and Impaired mtDNA Repair

A distinct and more specific mechanism, established in PNP-knockout mice: dGTP accumulating within mitochondria inhibits mitochondrial DNA repair, so T cells become hypersensitive to the spontaneous mitochondrial DNA damage they would ordinarily tolerate. The knockout mice reproduce the human pattern - T lymphocytes affected more severely than B, impaired thymocyte differentiation, reduced peripheral T cells - and their T cells show increased apoptosis in vivo and heightened sensitivity to gamma irradiation in vitro. The irradiation-sensitivity phenotype is directly corroborated in human cells: lymphoblastoid B cells from a patient with absent PNP activity survived irradiation markedly less well than cells from partial-deficiency patients or healthy controls.

T cell CL:0000084

mitochondrial DNA repair GO:0043504 ↓ DECREASED

Animal models

PNP-knockout mouse Mouse recapitulates The model is where this mechanism was established: mitochondrial dGTP accumulation inhibiting mtDNA repair, leaving T cells hypersensitive to spontaneous mitochondrial DNA damage.

Downstream

Thymocyte and Peripheral T Lymphocyte Apoptosis Unrepaired mitochondrial DNA damage triggers apoptosis of the T cells that carry it.

Show evidence (3 references)

PMID:10859343 SUPPORT Model Organism

"We propose that the immune deficiency in PNP deficiency is a result of inhibition of mitochondrial DNA repair due to the accumulation of dGTP in the mitochondria."

States the mitochondrial mechanism this node represents. Evidence source is MODEL_ORGANISM because the mechanism was established in PNP-knockout mice.

PMID:10859343 SUPPORT Model Organism

"T lymphocytes of PNP-deficient mice exhibit increased apoptosis in vivo and higher sensitivity to gamma irradiation in vitro."

Supplies the apoptosis and DNA-damage-sensitivity phenotype that links this node to the downstream T-cell death node.

PMID:32695102 SUPPORT In Vitro

"The survival of lymphoblastoid B cells from 2 partial PNP-deficient patients after irradiation was similar to that of PNP-proficient cells and markedly higher than the survival of cells from a patient with absent PNP activity"

Human-cell corroboration that DNA-damage sensitivity tracks residual PNP activity, which is what makes the murine mitochondrial mechanism credible for human disease.

Thymocyte and Peripheral T Lymphocyte Apoptosis

Converging nuclear and mitochondrial DNA insults drive apoptosis of thymocytes and peripheral T cells. This is the point at which a metabolic lesion becomes an immune one, and it explains a clinical peculiarity of PNP deficiency: T-cell function may be normal at birth and decline with time, or fluctuate between low and normal, because the defect is a progressive attritional loss of cells rather than a developmental failure to make them.

thymocyte CL:0000893 T cell CL:0000084

apoptotic process GO:0006915 ↑ INCREASED

Downstream

Impaired Thymocyte Development and Reduced T-Cell Output Loss of maturing thymocytes reduces the thymic production of peripheral T cells.

Show evidence (2 references)

PMID:10859343 SUPPORT Model Organism

"The end result is increased sensitivity of T cells to spontaneous mitochondrial DNA damage, leading to T cell depletion by apoptosis."

States apoptotic T-cell depletion as the endpoint of the metabolic chain, the content of this node. Evidence source is MODEL_ORGANISM.

PMID:1931007 SUPPORT Human Clinical

"T-cell function may be profoundly deficient, may be normal at birth and then decrease with time, or may fluctuate repeatedly between low and normal."

Documents the progressive and fluctuating T-cell course in patients, which is the clinical signature of attritional cell loss rather than a developmental block.

Impaired Thymocyte Development and Reduced T-Cell Output

The thymus fails as a T-cell factory: thymocyte differentiation is impaired and the numbers of maturing thymocytes and of peripheral T cells fall. Because the lesion is intrinsic to the haematopoietic compartment rather than to the thymic stroma, replacing the haematopoietic system corrects it - which is the mechanistic basis for transplantation being curative.

thymocyte CL:0000893

Animal models

PNP-knockout mouse Mouse recapitulates The model reproduces the human thymic phenotype closely: impaired thymocyte differentiation with reduced numbers of maturing thymocytes and peripheral T cells.

Downstream

T-Cell Predominant Combined Immunodeficiency Loss of thymic output produces the peripheral T-cell deficiency that defines the clinical immunodeficiency.

Show evidence (1 reference)

PMID:10859343 SUPPORT Model Organism

"PNP knockout mice exhibit impaired thymocyte differentiation, reduced mitogenic and allogeneic responses, and decreased numbers of maturing thymocytes and peripheral T cells."

Documents impaired thymocyte differentiation and reduced thymic output, the content of this node. Evidence source is MODEL_ORGANISM.

CNS Purine Nucleotide Imbalance

Purine imbalance extends to the central nervous system, and depressed GTP levels have been proposed to correlate with the neurological dysfunction. This node is deliberately curated as a proposal rather than an established chain: the mechanism connecting purine imbalance to neuronal dysfunction in PNP deficiency is not settled, the neurological arm is not explained by the T-cell mechanism, and transplantation corrects the immune defect without reliably reversing established neurological disease. See the `pnp-neurological-mechanism` knowledge gap.

Downstream

Neurological Dysfunction The intermediates between CNS purine imbalance and neuronal dysfunction are not established; the edge is asserted at low confidence and flagged as an open gap.

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"Depressed GTP levels may correlate with neurologic dysfunction."

The only mechanistic proposal available for the neurological arm, and the source itself states it only as a possible correlation. Recorded as PARTIAL for that reason.

T-Cell Predominant Combined Immunodeficiency

The resulting immunodeficiency is combined but asymmetric: T-cell numbers and function are profoundly affected while B-cell function is normal in most patients and deficient in roughly a third, and NK function is variable. Serum immunoglobulins are often normal or only slightly reduced, which is a diagnostic trap - normal immunoglobulins do not exclude the disease. PNP deficiency accounts for approximately 4% of severe combined immunodeficiency.

T cell CL:0000084 B cell CL:0000236

Downstream

Recurrent and Opportunistic Infection Loss of T-cell immunity permits recurrent bacterial and opportunistic infection.

Immune Dysregulation with Autoimmunity and EBV-Driven Lymphoma Defective T-cell regulation and surveillance permit autoimmunity and uncontrolled EBV-driven lymphoproliferation.

Show evidence (2 references)

PMID:1931007 SUPPORT Human Clinical

"B-cell function can be normal but is deficient in approximately one third of patients."

Quantifies the asymmetry between the T-cell and B-cell arms that defines this node.

PMID:1931007 SUPPORT Human Clinical

"Purine nucleoside phosphorylase (PNP) deficiency is a rare inherited disease accounting for approximately 4% of patients with severe combined immunodeficiency."

Places the disease quantitatively within the SCID population.

Recurrent and Opportunistic Infection

Recurrent respiratory and gastrointestinal infections, usually beginning in the first year of life, and opportunistic infections reflecting the T-cell defect. Infection is the commonest cause of death: in one four-patient series three died of sepsis during follow-up.

Show evidence (2 references)

PMID:1931007 SUPPORT Human Clinical

"PNP-deficient patients suffer from recurrent infections, usually beginning in the first year of life."

Establishes recurrent infection and its typical age of onset.

PMID:33061764 SUPPORT Human Clinical

"Three of the four patients were lost due to sepsis during follow-up, and one patient was lost due to veno-occlusive disease in the post-hematopoietic stem cell transplantation period."

Documents infection as the dominant cause of death in an untransplanted cohort, the basis for treating the condition as a paediatric emergency.

Immune Dysregulation with Autoimmunity and EBV-Driven Lymphoma

Loss of T-cell regulation and surveillance produces two distinct complications. Autoimmunity affects about a third of patients, most often autoimmune haemolytic anaemia, with immune thrombocytopenic purpura and lupus also reported. Separately, failure of T-cell control of Epstein-Barr virus permits EBV-associated lymphoma, which has repeatedly proved fatal before transplantation could be undertaken - a specific reason the diagnosis is urgent rather than merely serious.

Show evidence (2 references)

PMID:1931007 SUPPORT Human Clinical

"One third of patients develop autoimmune disease. The most common manifestation of this is autoimmune hemolytic anemia."

Quantifies the autoimmune arm and names its commonest manifestation.

PMID:31707514 SUPPORT Human Clinical

"One patient died of EBV-related lymphoma with CNS involvement prior to transplant."

Documents fatal EBV-driven lymphoma occurring before transplantation, the specific malignancy risk of this node.

Neurological Dysfunction

About two thirds of patients have neurological disease, ranging from spasticity through developmental delay to intellectual disability, and roughly a quarter first come to medical attention for neurological rather than infectious problems. The neurological arm is mechanistically separate from the immunological one: it is not explained by T-cell depletion, it is absent in some patients with full-blown immunodeficiency, and it is not reliably reversed by correcting the immune defect. Reported post-transplant neurological outcomes range from excellent to persistent mild developmental delay without further deterioration.

Show evidence (3 references)

PMID:1931007 SUPPORT Human Clinical

"Two thirds of patients have evidence of neurologic disorders. Findings range from spasticity to developmental delay, to mental retardation."

Quantifies the neurological arm and describes its range, the content of this node.

PMID:1931007 SUPPORT Human Clinical

"Patients usually present with infections but approximately one fourth have come to medical care initially for neurological problems."

Shows the neurological arm can be the presenting problem, supporting its status as a partly independent disease dimension.

PMID:30885031 SUPPORT Human Clinical

"PNP deficiency should be considered in late-onset children with recurrent infections, autoimmune disorders without typical neurologic impairment."

Documents a patient with full immunodeficiency and autoimmunity but no neurological dysfunction. Recorded as PARTIAL because it qualifies the neurological arm as non-obligate rather than supporting it.

Unrestrained TLR7 Signalling by Guanosine Nucleoside Ligands

This node resolves what would otherwise be the central paradox of the disease: how a profound T-cell immunodeficiency produces autoimmunity in a third of patients. PNP does not have one immunological job but two, in different lineages. In B lymphocytes and macrophages it controls the levels of the (deoxy)guanosine nucleosides that are the ligands of Toll-like receptor 7, so losing PNP removes a brake on innate nucleic-acid sensing. Overriding that brake drives germinal centre formation in the absence of any exogenous antigen and accelerates disease in a mouse autoimmunity model. Autoimmunity in PNP deficiency is therefore not merely the passive consequence of failed T-cell regulation - it has its own positive, lineage-specific mechanism running in parallel.

B cell CL:0000236 macrophage CL:0000235

toll-like receptor 7 signaling pathway GO:0034154 ↑ INCREASED

Downstream

Immune Dysregulation with Autoimmunity and EBV-Driven Lymphoma Unrestrained TLR7 signalling drives antigen-independent germinal centre formation and accelerates autoimmune disease.

Show evidence (3 references)

PMID:35653193 SUPPORT Model Organism

"In B lymphocytes and macrophages, PNP regulates Toll-like receptor 7 signaling by controlling the levels of its (deoxy)guanosine nucleoside ligands."

Establishes the lineage-specific TLR7 checkpoint that this node represents. Evidence source is MODEL_ORGANISM because the mechanism was established in mouse and cellular systems.

PMID:35653193 SUPPORT Model Organism

"Overriding this regulatory mechanism promotes germinal center formation in the absence of exogenous antigen and accelerates disease in a mouse model of autoimmunity."

Supplies the causal consequence of losing the TLR7 brake, which justifies the downstream edge to the immune-dysregulation node. Evidence source is MODEL_ORGANISM.

PMID:35653193 SUPPORT Model Organism

"This work reveals that one purine metabolism gene protects against immunodeficiency and autoimmunity via independent mechanisms operating in distinct immune lineages"

States explicitly that the immunodeficiency and autoimmunity arms are independent lineage-specific mechanisms, which is why they are modelled here as parallel branches rather than one causing the other.

SAMHD1-Dependent Synthetic Lethality in Developing T Cells

The T-cell arm is not simply dGTP toxicity but a gene-interaction effect. During T-cell development, PNP inactivation is synthetically lethal with downregulation of the dNTP triphosphohydrolase SAMHD1 - the enzyme that would otherwise dispose of excess dNTPs. Developing thymocytes physiologically downregulate SAMHD1, so they lose the very safeguard that would protect them from an accumulating dNTP load, which is a second and more specific explanation for why the disease targets the developing T-cell compartment. The interaction requires deoxycytidine kinase activity and is antagonised by microenvironmental deoxycytidine, so it is in principle a modifiable dependency.

thymocyte CL:0000893

Downstream

Thymocyte and Peripheral T Lymphocyte Apoptosis Loss of the SAMHD1 safeguard during T-cell development converts the dNTP burden into lethality for the developing thymocyte.

Show evidence (2 references)

PMID:35653193 SUPPORT Model Organism

"During T cell development, PNP inactivation is synthetically lethal with downregulation of the dNTP triphosphohydrolase SAMHD1."

Establishes the synthetic-lethal gene interaction that gives the T-cell arm its developmental-stage specificity. Evidence source is MODEL_ORGANISM.

PMID:35653193 SUPPORT Model Organism

"This interaction requires deoxycytidine kinase activity and is antagonized by microenvironmental deoxycytidine."

Identifies the kinase required for the toxic conversion and a microenvironmental antagonist, which is why the interaction is described here as potentially modifiable.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Blood 2

Autoimmune hemolytic anemia HP:0001890

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"One third of patients develop autoimmune disease. The most common manifestation of this is autoimmune hemolytic anemia."

Names autoimmune haemolytic anaemia as the commonest autoimmune manifestation.

Lymphoma HP:0002665

Show evidence (2 references)

PMID:31707514 SUPPORT Human Clinical

"One patient died of EBV-related lymphoma with CNS involvement prior to transplant."

Documents fatal EBV-driven lymphoma in a patient with PNP deficiency.

PMID:35063692 SUPPORT Human Clinical

"One patient died prior to HSCT due to EBV-associated lymphoma."

A second independent series reporting fatal EBV-associated lymphoma before transplantation.

Immune 3

Combined immunodeficiency HP:0005387

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"In PNP deficiency, T- and B-cell immunity are affected."

Establishes the combined character of the immunodeficiency.

Recurrent infections HP:0002719

Temporal: RECURRENT

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"PNP-deficient patients suffer from recurrent infections, usually beginning in the first year of life."

Establishes recurrent infection and its typical onset.

Autoimmunity FREQUENT HP:0002960

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"One third of patients develop autoimmune disease. The most common manifestation of this is autoimmune hemolytic anemia."

One third is approximately 33%, at the lower edge of the FREQUENT band (30-79%), and is the quantitative basis for the frequency asserted here.

Musculoskeletal 2

Spasticity HP:0001257

Show evidence (2 references)

PMID:1931007 SUPPORT Human Clinical

"Findings range from spasticity to developmental delay, to mental retardation."

Names spasticity as part of the neurological spectrum.

PMID:39772979 SUPPORT Human Clinical

"We report the case of a 6-year-old boy who presented with muscular hypertonia, impaired growth, and recurrent infections"

Documents hypertonia as a presenting feature in a genetically confirmed patient.

Hypertonia HP:0001276

Show evidence (2 references)

PMID:33061764 SUPPORT Human Clinical

"Developmental retardation, hypertonia, spasticity, tremors, ataxia, and motor retardation are observed frequently."

Names hypertonia among the frequently observed neurological findings.

PMID:39772979 SUPPORT Human Clinical

"We report the case of a 6-year-old boy who presented with muscular hypertonia, impaired growth, and recurrent infections"

Documents hypertonia as a presenting feature in a genetically confirmed patient.

Nervous System 5

Global developmental delay FREQUENT HP:0001263

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"Two thirds of patients have evidence of neurologic disorders. Findings range from spasticity to developmental delay, to mental retardation."

Two thirds is approximately 67%, which falls in the FREQUENT band (30-79%) and is the quantitative basis for the frequency asserted here.

Ataxia HP:0001251

Show evidence (2 references)

PMID:33061764 SUPPORT Human Clinical

"Developmental retardation, hypertonia, spasticity, tremors, ataxia, and motor retardation are observed frequently."

Names ataxia directly among the neurological findings frequently observed in patients with PNP deficiency.

PMID:33061764 SUPPORT Human Clinical

"Cranial MRI reveals cerebral cortical and cerebellar atrophy and white matter demyelination"

Supplies the cerebellar structural correlate that makes ataxia a coherent finding rather than an isolated symptom report.

Tremor HP:0001337

Show evidence (1 reference)

PMID:33061764 SUPPORT Human Clinical

"Developmental retardation, hypertonia, spasticity, tremors, ataxia, and motor retardation are observed frequently."

Names tremor among the frequently observed neurological findings.

Cerebellar atrophy HP:0001272

Show evidence (1 reference)

PMID:33061764 SUPPORT Human Clinical

"Cranial MRI reveals cerebral cortical and cerebellar atrophy and white matter demyelination"

Documents the imaging findings, including cerebellar atrophy, in PNP deficiency.

Intellectual disability HP:0001249

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"Findings range from spasticity to developmental delay, to mental retardation."

Names the most severe cognitive endpoint of the neurological spectrum. The source's historical terminology is quoted verbatim as required; the curated term uses current HPO nomenclature.

Growth 1

Failure to thrive HP:0001508

Show evidence (1 reference)

PMID:35063692 SUPPORT Human Clinical

"They present clinically with recurrent infections, failure to thrive, various neurological disorders, malignancies, and autoimmune diseases."

Lists failure to thrive among the presenting clinical features.

Other 2

Decreased total T cell count HP:0005403

Course: PROGRESSIVE

Show evidence (2 references)

PMID:30885031 SUPPORT Human Clinical

"a rare autosomal recessive primary immunodeficiency disorder characterized by decreased numbers of T-cells, variable B-cell abnormalities, decreased amount of serum uric acid and PNP enzyme activity"

Names decreased T-cell numbers as a defining feature of the disorder.

PMID:1931007 SUPPORT Human Clinical

"T-cell function may be profoundly deficient, may be normal at birth and then decrease with time, or may fluctuate repeatedly between low and normal."

Documents the progressive and fluctuating course that makes a single normal T-cell result non-exclusionary.

Hypouricemia HP:0003537

Show evidence (1 reference)

PMID:33061764 SUPPORT Human Clinical

"Absolute lymphocyte counts and serum uric acid levels were very low, and serum immunoglobulin levels were normal or slightly lower in all cases."

Documents low serum uric acid in all four cases of a confirmed case series, alongside the deceptively normal immunoglobulins.

🧬

Genetic Associations

PNP (Biallelic loss-of-function variants)

Gene: PNP hgnc:7892 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:1931007 SUPPORT Human Clinical

"The gene for PNP has been cloned; it is located on the long arm of chromosome 14. Studies of a mutant PNP gene isolated from one patient showed that a point mutation resulting in an amino acid substitution was responsible for PNP deficiency."

Establishes PNP as the causative gene, its chromosomal location, and a point mutation as a demonstrated mechanism of enzyme loss.

PMID:39772979 SUPPORT Human Clinical

"One hemizygous variant was c.385dup (p.Ile129Asnfs*6) in exon 4. The other was a heterozygous deletion in exon 2-6."

Documents the allelic spectrum beyond missense change, including frameshift and multi-exon deletion alleles.

💊

Medical Actions

Allogeneic haematopoietic stem cell transplantation

Action: Hematopoietic Cell Transplantation NCIT:C15431

The only available cure. Replacing the patient's haematopoietic system with PNP-competent donor cells restores enzyme activity in the lymphoid compartment where the substrate burden is greatest, giving durable immune reconstitution. Reported outcomes are good when transplantation is performed in time - three of four patients in one Israeli series achieved good immune reconstitution over 8 to 108 months of follow-up with excellent neurological outcomes - but the qualifier matters: the fourth patient died of EBV-related lymphoma before transplant, and in a Turkish series a patient was lost to veno-occlusive disease after transplant. Neurological disease already established is not reliably reversed, though post-transplant series report no further deterioration.

Mechanism Target:

INHIBITS Loss of Purine Nucleoside Phosphorolysis — Donor-derived haematopoiesis supplies PNP-competent cells to the lymphoid compartment, restoring the missing phosphorolysis step where the substrate burden is greatest. This is why the therapeutic logic is metabolic rather than merely immunological, and why replacing the haematopoietic compartment suffices: the enzymatic lesion that matters is intrinsic to it. The partial-deficiency data suggest the bar is low, since 8-11% of normal activity supported near-normal immunity.

INHIBITS Impaired Thymocyte Development and Reduced T-Cell Output — Restoring enzyme-competent haematopoiesis re-establishes thymocyte development and peripheral T-cell output. Neurological disease already established at the time of transplant is not reliably reversed, which is the principal limit of the approach.

INHIBITS T-Cell Predominant Combined Immunodeficiency — Restoring enzyme-competent T-cell development corrects the combined immunodeficiency.

Show evidence (3 references)

PMID:35063692 SUPPORT Human Clinical

"Hematopoietic stem cell transplantation (HSCT) is the only available cure for patients with PNP deficiency."

Establishes transplantation as the only curative option.

PMID:31707514 SUPPORT Human Clinical

"HSCT offers a good treatment option, with excellent clinical outcomes, when preformed in a timely manner."

Supports transplantation with the timing qualifier that governs its success.

PMID:35063692 SUPPORT Human Clinical

"Over the course of post-HSCT, there was no further aggravation of the patients' neurological symptoms. Although both of the patients still had mild developmental delay, new developmental milestones were achieved."

Documents that transplantation halts but does not reverse established neurological disease. Recorded as PARTIAL because it both supports the treatment and bounds what it achieves.

Supportive care and infection prophylaxis

Action: Supportive Care NCIT:C15747

Immunoglobulin replacement, antimicrobial prophylaxis and irradiated, CMV-safe blood products bridge the patient to transplantation. This is explicitly a bridge and not a treatment of the disease: no supportive or dietary approach has been consistently successful, and the older attempts - red cell transfusion to supply enzyme, dietary purine and pyrimidine supplementation - did not work.

Mechanism Target:

INHIBITS Recurrent and Opportunistic Infection — Prophylaxis and immunoglobulin replacement reduce the infection burden without altering the underlying enzyme defect.

Show evidence (1 reference)

PMID:1931007 SUPPORT Human Clinical

"Many different therapies have been utilized for PNP deficiency including bone marrow transplantation, red cell transfusions, and supplementation of the diet with purines and pyrimidines. None of these therapies has been consistently successful."

Documents the historical failure of non-transplant approaches. Recorded as PARTIAL because it establishes what supportive care cannot do rather than supporting an effective therapy; note the review predates modern transplant outcomes, which are curated separately above.

🔬

Biochemical Markers

Serum uric acid

Show evidence (2 references)

PMID:33061764 SUPPORT Human Clinical

"Absolute lymphocyte counts and serum uric acid levels were very low, and serum immunoglobulin levels were normal or slightly lower in all cases."

Documents markedly low serum uric acid in all four cases of a confirmed series.

PMID:32695102 SUPPORT Human Clinical

"All siblings had normal blood uric acid and increased PNP substrates in the urine."

Bounds the marker: normal urate in partial deficiency, so a normal value does not exclude the diagnosis. Recorded as PARTIAL for that reason.

Urinary purine nucleosides

Show evidence (2 references)

PMID:32695102 SUPPORT Human Clinical

"All siblings had normal blood uric acid and increased PNP substrates in the urine."

Shows urinary substrate elevation persisting when serum urate is normal, establishing it as the more sensitive marker.

PMID:24767876 SUPPORT Human Clinical

"caused by a enzyme defect leading to the accumulation of inosine, 2'-deoxy-inosine (dIno), guanosine, and 2'-deoxy-guanosine (dGuo) in all cells, especially lymphocytes"

Names the four accumulating substrates measured in this profile.

🔬

Diagnosis

Purine nucleoside phosphorylase enzyme activity assay

Demonstration of absent or severely reduced PNP catalytic activity, conventionally measured by conversion of labelled inosine in erythrocyte haemolysates, mononuclear cells or lymphoblastoid cells, is the confirmatory biochemical test. Quantitation rather than a simple present/absent result matters here, because residual activity predicts phenotype: 8-11% of normal was compatible with survival into the third decade and normal neurological development.

enzyme activity assay NCIT:C25294

Results: Absent or severely reduced PNP activity confirms the diagnosis; residual activity should be quantified because it predicts severity.

Show evidence (2 references)

PMID:32695102 SUPPORT Human Clinical

"PNP protein expression was determined by Western Blotting in lymphoblastoid B cells. DNA repair was quantified by measuring viability of lymphoblastoid B cells following ionizing irradiation."

Describes the specimen types and the paired protein-expression and DNA-repair assays used to characterise PNP deficiency, complementing the catalytic-activity measurement.

PMID:30885031 SUPPORT Human Clinical

"characterized by decreased numbers of T-cells, variable B-cell abnormalities, decreased amount of serum uric acid and PNP enzyme activity"

Names reduced PNP enzyme activity, alongside T-cell depletion and low uric acid, as a defining diagnostic feature.

Plasma and urine purine metabolite profiling

Quantitation of inosine, deoxyinosine, guanosine and deoxyguanosine with serum uric acid. The characteristic pattern is raised PNP substrates with low urate. The urinary substrate elevation is the more sensitive half of the pair: in partial deficiency blood uric acid was entirely normal while urinary PNP substrates were still raised, so a normal urate does not exclude the diagnosis.

metabolite profiling NCIT:C25294

Results: Elevated inosine, guanosine, deoxyinosine and deoxyguanosine in plasma and urine with low serum uric acid.

Show evidence (2 references)

PMID:24767876 SUPPORT Human Clinical

"caused by a enzyme defect leading to the accumulation of inosine, 2'-deoxy-inosine (dIno), guanosine, and 2'-deoxy-guanosine (dGuo) in all cells, especially lymphocytes"

Names the four accumulating metabolites that constitute the diagnostic profile.

PMID:32695102 SUPPORT Human Clinical

"All siblings had normal blood uric acid and increased PNP substrates in the urine."

Demonstrates that urinary substrate elevation persists when serum urate is normal, which is why urate alone is an inadequate screen.

Lymphocyte subset enumeration and immune function testing

T, B and NK cell counts with immunoglobulins and proliferation responses. Two traps are worth recording. Serum immunoglobulins are frequently normal or only slightly reduced, so normal immunoglobulins do not exclude the diagnosis. And T-cell counts may be normal at birth and decline with time or fluctuate, because the defect is progressive attritional apoptosis rather than a developmental block - so a single normal result is not exclusionary either.

immunophenotyping NCIT:C25294

Results: Reduced T-cell numbers with variable B and NK abnormalities; immunoglobulins may be normal.

Show evidence (1 reference)

PMID:33061764 SUPPORT Human Clinical

"Absolute lymphocyte counts and serum uric acid levels were very low, and serum immunoglobulin levels were normal or slightly lower in all cases."

Documents the lymphopenia-with-normal-immunoglobulins pattern that makes this a diagnostic trap.

PNP gene sequencing with deletion and duplication analysis

Confirmation of biallelic pathogenic PNP variants. Sequencing alone is insufficient: the reported allelic spectrum includes multi-exon deletions as well as point and frameshift variants, so copy-number analysis has to accompany sequence analysis or a second allele can be missed. Whole-exome sequencing has been the route to diagnosis in several reported atypical presentations.

molecular genetic testing NCIT:C15709

Results: Two pathogenic PNP alleles confirm the diagnosis; deletion/duplication analysis is required alongside sequencing.

Show evidence (2 references)

PMID:39772979 SUPPORT Human Clinical

"One hemizygous variant was c.385dup (p.Ile129Asnfs*6) in exon 4. The other was a heterozygous deletion in exon 2-6."

A compound genotype pairing a frameshift with a multi-exon deletion, which is exactly the case sequencing alone would fail to resolve.

PMID:30885031 SUPPORT Human Clinical

"In this study, whole-exome sequencing was used to detect mutation in the case suspected of having primary immunodeficiency."

Documents whole-exome sequencing as the diagnostic route in an atypical presentation.

Newborn screening by TREC/KREC and dried-blood-spot tandem mass spectrometry

Two complementary newborn-screening routes exist and the distinction matters. Tandem mass spectrometry on dried blood spots detects the purine metabolite signature directly and was the original route; TREC/KREC analysis detects the downstream T-cell lymphopenia and can also pick the disease up, as first reported in 2021. Because transplantation is curative but its success depends on being early - and because EBV-driven lymphoma before transplant is a documented cause of death - presymptomatic detection is unusually consequential here. A TREC-based screen may still miss milder or evolving disease, since it detects the consequence rather than the metabolic defect.

newborn screening NCIT:C81178

Results: Reduced TREC/KREC copy number and/or an abnormal dried-blood-spot purine profile prompt confirmatory enzyme and molecular testing.

Show evidence (3 references)

PMID:24767876 SUPPORT Human Clinical

"Treatments are available and curative for PNP deficiency, but their efficacy depends on the early approach. PNP-combined immunodeficiency complies with the criteria for inclusion in a newborn screening program."

States the rationale for newborn screening - a curative treatment whose success is time-dependent - and the mass-spectrometry route.

PMID:34698070 SUPPORT Human Clinical

"To date, PNP deficiency has been detected in newborn screening only through the use of liquid chromatography tandem mass spectrometry. We report the first case in which PNP deficiency was detected by TREC analysis."

Documents the TREC route as a second, later-established screening modality distinct from mass spectrometry.

PMID:40981309 SUPPORT Human Clinical

"Ukraine successfully carried out NBS on a neonatal dried blood spot (DBS) by real-time PCR, which showed remarkably reduced T-cell receptor and kappa-deleting recombination excision circles (TREC/KREC)."

A worked case of TREC/KREC screening detecting PNP deficiency and leading to successful transplantation, demonstrating the screening-to-cure pathway in practice.

🔬

Clinical Trials

NCT06092346 NOT_APPLICABLE RECRUITING

An NIH prospective observational natural-history protocol covering disorders of pyrimidine and purine metabolism, of which PNP deficiency is one. Observational rather than interventional, and relevant because the entry's principal knowledge gap - the mechanism and time course of the neurological arm - is exactly the kind of question a natural-history cohort with systematic phenotyping is positioned to answer.

Target Phenotypes: Global developmental delay HP:0001263 Combined immunodeficiency HP:0005387

Show evidence (1 reference)

clinicaltrials:NCT06092346 SUPPORT Human Clinical

"DPPMs can cause dysfunctions throughout the body, especially in the brain, blood, kidneys, and immune system."

States the scope of the natural-history protocol, covering the neurological and immune dimensions that are this entry's two disease arms.

🐁

Animal Models

PNP-knockout mouse

Purpose-built to interrogate the mechanism of the human immunodeficiency, and the source of the mitochondrial hypothesis this entry curates. It reproduces the defining asymmetry of the human disease - T lymphocytes affected more severely than B - with impaired thymocyte differentiation, reduced mitogenic and allogeneic responses, and decreased numbers of maturing thymocytes and peripheral T cells.

Species

Mouse

Genotype

Pnp-deficient (knockout)

Publication

PMID:10859343

Pathograph links

Mitochondrial dGTP Accumulation and Impaired mtDNA Repair recapitulates fidelity: moderate The model is where this mechanism was established: mitochondrial dGTP accumulation inhibiting mtDNA repair, leaving T cells hypersensitive to spontaneous mitochondrial DNA damage.

Limitations: The mechanism is proposed from the murine phenotype and has not been demonstrated directly in human PNP-deficient tissue. The nearest human corroboration is indirect - irradiation survival of patient lymphoblastoid B cells tracking residual PNP activity - which supports DNA-damage hypersensitivity without confirming the mitochondrial locus. Notably, an independent PNP-deficient mouse line failed to show dGTP accumulation in thymocytes or spleen leucocytes at all, and instead had a secondary deficiency of deoxyguanosine kinase, so the murine metabolic phenotype is not uniform across lines.

Readouts

T lymphocyte apoptosis and gamma-irradiation sensitivity

Direction: INCREASED

Interpretation: Increased apoptosis in vivo with heightened sensitivity to DNA damage in vitro is the functional signature of impaired repair capacity.

Show evidence (1 reference)

PMID:10859343 SUPPORT Model Organism

"T lymphocytes of PNP-deficient mice exhibit increased apoptosis in vivo and higher sensitivity to gamma irradiation in vitro."

Reports the apoptosis and DNA-damage-sensitivity measurements underpinning this node.

Show evidence (1 reference)

PMID:10859343 SUPPORT Model Organism

"We propose that the immune deficiency in PNP deficiency is a result of inhibition of mitochondrial DNA repair due to the accumulation of dGTP in the mitochondria."

Supports treating this model as the source of, and evidence for, the mitochondrial node.

Impaired Thymocyte Development and Reduced T-Cell Output recapitulates fidelity: high The model reproduces the human thymic phenotype closely: impaired thymocyte differentiation with reduced numbers of maturing thymocytes and peripheral T cells.

Limitations: Murine and human thymic development differ in tempo and in the duration of thymic output, so the timing of decline is not directly transferable; the model also does not reproduce the fluctuating T-cell counts described in patients.

Readouts

Maturing thymocyte and peripheral T-cell numbers

Direction: DECREASED

Interpretation: Reduced thymocyte and peripheral T-cell numbers are the direct measurement of failed thymic output.

Show evidence (1 reference)

PMID:10859343 SUPPORT Model Organism

"PNP knockout mice exhibit impaired thymocyte differentiation, reduced mitogenic and allogeneic responses, and decreased numbers of maturing thymocytes and peripheral T cells."

Reports the thymocyte and peripheral T-cell measurements for this node.

Show evidence (1 reference)

PMID:10859343 SUPPORT Model Organism

"Similar to the human disease, PNP deficiency in mice causes an immunodeficiency that affects T lymphocytes more severely than B lymphocytes."

States the correspondence with the human disease that justifies treating this model as informative for the thymic node.

B6-NPE / B6-NPF ENU-induced PNP-deficient mouse strains

Chemically induced hypomorphic Pnp mutants, predating the Arpaia knockout by six years and carrying residual enzyme activity rather than a null allele. They are curated as a separate model precisely because the negative result below is theirs and not the knockout's: a hypomorph failing to accumulate dGTP is a materially weaker negative than a null failing to, and attaching that claim to the field's principal model would overstate it.

Species

Mouse

Genotype

Pnp hypomorphic ENU-induced point mutants (B6-NPE, B6-NPF); residual PNP activity with a secondary deficiency of deoxyguanosine kinase

Publication

PMID:7918681

Pathograph links

Intracellular dGTP Pooling in Lymphoid Cells fails to recapitulate fidelity: low This is the honest negative result, and it is the structural counterpart of the HUMAN_MODEL_MISMATCH discussion. In the B6-NPE and B6-NPF PNP-deficient mouse lines, the dGTP accumulation that the whole human mechanism is built on was not detectable in thymocytes, spleen leucocytes or erythrocytes, and there were no changes in purine or pyrimidine ribonucleotide pools. The lines instead showed a secondary deficiency of deoxyguanosine kinase, which would prevent the toxic phosphorylation step from running - so the mouse partly protects itself from the very lesion the model is meant to represent.

Limitations: This failure is line-specific rather than a property of murine PNP deficiency in general, and it does not overturn the mitochondrial hypothesis; it does mean that a murine failure to accumulate dGTP cannot be read as evidence about the human metabolic phenotype, and that dGTP-pooling claims must rest on human data.

Readouts

dGTP concentration in thymocytes, spleen leucocytes and erythrocytes

Direction: UNCHANGED

Interpretation: No detectable dGTP accumulation in the very compartments where the human mechanism predicts it - a genuine negative measurement, not an absence of testing.

Show evidence (1 reference)

PMID:7918681 REFUTE Model Organism

"We found no evidence for dGTP accumulation in thymocytes or spleen leucocytes, < 1 nmol/10(9) cells, nor in erythrocytes, < 0.05 nmol/10(9) cells, of the B6-NPE- or B6-NPF PNP-deficient mice strains."

Directly reports the absence of dGTP accumulation in these mouse lines, which is why this link is recorded as FAILS_TO_RECAPITULATE.

Show evidence (2 references)

PMID:7918681 REFUTE Model Organism

The substantive negative finding required to justify a FAILS_TO_RECAPITULATE link.

+ 1 more reference

{ }

Source YAML

click to show

name: Purine nucleoside phosphorylase deficiency
creation_date: '2026-08-19T23:40:00Z'
category: Inborn Error of Metabolism
description: >-
  Purine nucleoside phosphorylase (PNP) deficiency is an autosomal recessive inborn
  error of the purine salvage pathway causing a combined immunodeficiency that falls
  predominantly on T cells, together with neurological disease and autoimmunity. It
  accounts for roughly 4% of severe combined immunodeficiency.

  The mechanism is a substrate-toxicity chain rather than a loss of product. PNP
  normally phosphorolyses inosine, guanosine and their deoxy forms; without it,
  deoxyguanosine accumulates and is phosphorylated to dGTP, a conversion that in the
  T-cell-lethal arm requires deoxycytidine kinase.
  PNP is expressed in most tissues but at its highest levels in lymphoid tissue, which
  is why an enzyme defect present in every cell produces a disease of the lymphoid
  system. Elevated dGTP is thought to inhibit ribonucleotide reductase and so impede
  cell division; a complementary and more specific mechanism, established in
  PNP-knockout mice, is that mitochondrial dGTP accumulation inhibits mitochondrial DNA
  repair, leaving T cells hypersensitive to spontaneous mitochondrial DNA damage and
  driving their depletion by apoptosis. Thymocytes and peripheral T cells die, thymic
  output fails, and combined immunodeficiency follows.

  Two features make this entry more than a metabolic chain. First, the neurological arm
  - spasticity, developmental delay, ataxia - is present in about two thirds of patients
  and is NOT explained by the T-cell mechanism; its basis remains genuinely unresolved
  and is curated as an open knowledge gap rather than asserted. Second, the disease has a
  demonstrated activity threshold: siblings with roughly 8-11% residual PNP activity
  reached their third decade with mild immune abnormalities and entirely normal
  neurological development, which sets a quantitative floor on how much enzyme is
  actually needed and is directly relevant to what any future enzyme- or gene-directed
  therapy must achieve.
disease_term:
  preferred_term: purine nucleoside phosphorylase deficiency
  term:
    id: MONDO:0013171
    label: purine nucleoside phosphorylase deficiency
synonyms:
- PNP deficiency
- PNPase deficiency
- Immunodeficiency due to purine nucleoside phosphorylase deficiency
- Purine-nucleoside phosphorylase deficiency
parents:
- Inborn disorder of purine metabolism
- Combined immunodeficiency
- Inborn error of metabolism
inheritance:
- name: Autosomal recessive
  description: >-
    Biallelic loss-of-function variants in PNP on chromosome 14q are required; carriers
    with one functional allele are unaffected, and the demonstration that 8-11% residual
    activity supports near-normal immunity explains why heterozygotes are healthy.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:30885031
    reference_title: >-
      The First Purine Nucleoside Phosphorylase Deficiency Patient Resembling IgA
      Deficiency and a Review of the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Purine nucleoside phosphorylase (PNP) deficiency is a rare autosomal recessive
      primary immunodeficiency disorder characterized by decreased numbers of T-cells,
      variable B-cell abnormalities, decreased amount of serum uric acid and PNP enzyme
      activity.
    explanation: >-
      States the autosomal recessive inheritance together with the defining immunological
      and biochemical features.

classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
    evidence:
    - reference: PMID:35063692
      reference_title: >-
        Combined immunodeficiency due to purine nucleoside phosphorylase deficiency:
        Outcome of three patients.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Purine nucleoside phosphorylase (PNP) is a key enzyme in the purine salvage
        pathway. PNP deficiency, caused by the autosomal recessive mutations in the PNP
        gene, can lead to severe combined immunodeficiency (SCID).
      explanation: >-
        PNP deficiency is an inherited enzyme defect of purine metabolism, placing it in
        Harrison's Endocrinology and Metabolism Part; its immunological expression is
        captured by the IMMUNE_RHEUMATOLOGIC classification below.
  - classification_value: IMMUNE_RHEUMATOLOGIC
    evidence:
    - reference: PMID:30885031
      reference_title: >-
        The First Purine Nucleoside Phosphorylase Deficiency Patient Resembling IgA
        Deficiency and a Review of the Literature.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Purine nucleoside phosphorylase (PNP) deficiency is a rare autosomal recessive
        primary immunodeficiency disorder characterized by decreased numbers of T-cells
      explanation: >-
        The clinical presentation is a primary immunodeficiency, placing the disease also
        in Harrison's Immune System and Rheumatologic Disorders Part.

genetic:
- name: PNP
  association: Biallelic loss-of-function variants
  gene_term:
    preferred_term: PNP
    term:
      id: hgnc:7892
      label: PNP
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    PNP is located on the long arm of chromosome 14. Reported pathogenic variants include
    missense substitutions abolishing catalytic activity, frameshifts and multi-exon
    deletions; a partial-activity missense allele (p.His257Asp) leaves 8-11% residual
    activity and a strikingly mild phenotype. The encoded protein is a trimer expressed in
    most tissues but at highest level in lymphoid tissue, which is the reason a
    ubiquitously expressed enzyme defect produces a predominantly lymphoid disease.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The gene for PNP has been cloned; it is located on the long arm of chromosome 14.
      Studies of a mutant PNP gene isolated from one patient showed that a point mutation
      resulting in an amino acid substitution was responsible for PNP deficiency.
    explanation: >-
      Establishes PNP as the causative gene, its chromosomal location, and a point
      mutation as a demonstrated mechanism of enzyme loss.
  - reference: PMID:39772979
    reference_title: >-
      Hematopoietic stem cell transplantation for purine nucleoside phosphorylase
      deficiency with two novel mutations: a case report and review of literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One hemizygous variant was c.385dup (p.Ile129Asnfs*6) in exon 4. The other was a
      heterozygous deletion in exon 2-6.
    explanation: >-
      Documents the allelic spectrum beyond missense change, including frameshift and
      multi-exon deletion alleles.

pathophysiology:
- name: Biallelic PNP Loss-of-Function Variants
  biological_scale: MOLECULAR
  role: trigger
  description: >-
    Inheritance of two defective PNP alleles abolishes or severely reduces purine
    nucleoside phosphorylase activity in every cell. Because one functional allele
    suffices for health, and because as little as 8-11% of normal activity supports
    near-normal immunity and entirely normal neurological development, the disease
    requires near-complete enzyme loss rather than mere reduction.
  downstream:
  - target: Loss of Purine Nucleoside Phosphorolysis
    causal_link_type: DIRECT
    description: >-
      Loss-of-function alleles remove the catalytic activity that this step depends on.
  evidence:
  - reference: PMID:32695102
    reference_title: >-
      Partial Purine Nucleoside Phosphorylase Deficiency Helps Determine Minimal Activity
      Required for Immune and Neurological Development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PNP activity in various cells from two patients were 8-11% of the normal level.
    explanation: >-
      Establishes the residual-activity threshold: this level of activity was compatible
      with survival into the third decade and normal neurological development, so the
      severe disease requires near-complete loss.

- name: Loss of Purine Nucleoside Phosphorolysis
  biological_scale: MOLECULAR
  role: central_effector
  description: >-
    PNP catalyses the phosphorolysis of inosine, guanosine, deoxyinosine and
    deoxyguanosine in the purine salvage pathway. Losing that step blocks the route from
    these nucleosides onward to hypoxanthine, xanthine and ultimately uric acid, and
    leaves the substrates to accumulate. The disease is therefore driven by what builds up
    behind the block rather than by any product the cell fails to make.
  molecular_functions:
  - preferred_term: purine-nucleoside phosphorylase activity
    modifier: LOSS_OF_FUNCTION
    term:
      id: GO:0004731
      label: purine-nucleoside phosphorylase activity
  biological_processes:
  - preferred_term: purine nucleoside catabolic process
    modifier: DECREASED
    term:
      id: GO:0006152
      label: purine nucleoside catabolic process
  downstream:
  - target: Accumulation of Deoxyguanosine and Other PNP Substrates
    causal_link_type: DIRECT
    description: >-
      Blocking phosphorolysis causes the enzyme's own substrates to accumulate in cells
      and body fluids.
  - target: Hypouricemia and Elevated Urinary Purine Nucleosides
    causal_link_type: DIRECT
    description: >-
      With the catabolic route to uric acid interrupted, serum urate falls and unmetabolised
      nucleosides are excreted.
  evidence:
  - reference: PMID:35063692
    reference_title: >-
      Combined immunodeficiency due to purine nucleoside phosphorylase deficiency: Outcome
      of three patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Purine nucleoside phosphorylase (PNP) is a key enzyme in the purine salvage pathway.
    explanation: >-
      Places the lost enzymatic step in the purine salvage pathway, which is the content of
      this node.

- name: Hypouricemia and Elevated Urinary Purine Nucleosides
  biological_scale: MOLECULAR
  role: biomarker
  description: >-
    Because uric acid is the end product of the interrupted pathway, serum urate is
    characteristically low - often strikingly so - and unmetabolised PNP substrates appear
    in the urine. This pairing is the cheap, widely available diagnostic clue that
    distinguishes PNP deficiency from other combined immunodeficiencies, and low uric acid
    in a lymphopenic infant should prompt the specific enzyme assay. Notably, urinary
    substrate elevation is the more sensitive of the two: partial-deficiency patients had
    entirely normal blood uric acid yet still excreted increased PNP substrates.
  evidence:
  - reference: PMID:33061764
    reference_title: >-
      Recurrent infections, neurologic signs, low serum uric acid levels, and lymphopenia in
      childhood: Purine nucleoside phosphorylase deficiency, an emergency for infants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Absolute lymphocyte counts and serum uric acid levels were very low, and serum
      immunoglobulin levels were normal or slightly lower in all cases.
    explanation: >-
      Documents the low serum uric acid with lymphopenia in all four cases of a case series,
      the diagnostic signature this node represents.
  - reference: PMID:32695102
    reference_title: >-
      Partial Purine Nucleoside Phosphorylase Deficiency Helps Determine Minimal Activity
      Required for Immune and Neurological Development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All siblings had normal blood uric acid and increased PNP substrates in the urine.
    explanation: >-
      Shows the two biochemical markers dissociate in partial deficiency - urate normal,
      urinary substrates raised. Recorded as PARTIAL because it supports the urinary marker
      while contradicting hypouricemia as a universal finding.

- name: Accumulation of Deoxyguanosine and Other PNP Substrates
  biological_scale: MOLECULAR
  role: central_effector
  description: >-
    Inosine, guanosine, deoxyinosine and above all deoxyguanosine accumulate behind the
    enzymatic block. Deoxyguanosine is the toxic species: unlike the ribonucleosides it can
    be phosphorylated onward to a deoxynucleotide triphosphate, and it is this conversion
    that converts a metabolic block into cell death.
  downstream:
  - target: Intracellular dGTP Pooling in Lymphoid Cells
    causal_link_type: DIRECT
    description: >-
      Accumulated deoxyguanosine is phosphorylated to dGTP, which is the proximate toxin;
      the T-cell-lethal arm of this conversion requires deoxycytidine kinase activity.
  - target: CNS Purine Nucleotide Imbalance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Systemic purine imbalance extends to the central nervous system, but the intermediates
      linking it to neuronal dysfunction are not established - see the
      `pnp-neurological-mechanism` knowledge gap.
  - target: Unrestrained TLR7 Signalling by Guanosine Nucleoside Ligands
    causal_link_type: DIRECT
    description: >-
      The same accumulating (deoxy)guanosine nucleosides are ligands for TLR7, so the
      metabolic block simultaneously removes a brake on innate nucleic-acid sensing.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The elevated dGTP found in PNP deficiency is thought to inhibit ribonucleotide
      reductase and, thus, impede cell division.
    explanation: >-
      Establishes deoxyguanosine-derived dGTP as the accumulating toxic species and names
      the classical downstream target.

- name: Intracellular dGTP Pooling in Lymphoid Cells
  biological_scale: MOLECULAR
  role: central_effector
  description: >-
    Deoxyguanosine is phosphorylated to dGTP, which pools to toxic concentrations
    preferentially in lymphoid cells. The tissue selectivity is the crux of the disease and
    has a simple explanation: PNP is expressed in most tissues but at its highest levels in
    lymphoid tissue, so lymphoid cells carry the largest flux through the missing step and
    the largest substrate burden when it fails. This is why a ubiquitously expressed enzyme
    defect produces a predominantly lymphoid disease.
  cell_types:
  - preferred_term: thymocyte
    term:
      id: CL:0000893
      label: thymocyte
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  downstream:
  - target: Ribonucleotide Reductase Inhibition and Impaired DNA Replication
    causal_link_type: DIRECT
    description: >-
      dGTP is an allosteric inhibitor of ribonucleotide reductase, distorting the
      deoxyribonucleotide pools required for DNA synthesis.
  - target: Mitochondrial dGTP Accumulation and Impaired mtDNA Repair
    causal_link_type: DIRECT
    description: >-
      dGTP accumulating in mitochondria inhibits mitochondrial DNA repair.
  - target: SAMHD1-Dependent Synthetic Lethality in Developing T Cells
    causal_link_type: DIRECT
    description: >-
      The synthetic-lethal interaction is not a standing property of the thymocyte but is
      created by the accumulating dNTP load: SAMHD1 is the triphosphohydrolase that would
      dispose of it, and developing thymocytes physiologically downregulate SAMHD1, so the
      dGTP burden arrives in the one cell type that has stood down its disposal capacity.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is found in most tissues of the body but is at highest levels in lymphoid tissues.
      This tissue distribution explains why the lymphoid system is predominantly affected in
      PNP deficiency.
    explanation: >-
      Supplies the explanation for the lymphoid selectivity that is the defining feature of
      this node.

- name: Ribonucleotide Reductase Inhibition and Impaired DNA Replication
  biological_scale: CELLULAR
  role: central_effector
  description: >-
    Elevated dGTP allosterically inhibits ribonucleotide reductase, the enzyme that
    supplies deoxyribonucleotides for DNA synthesis. The consequence is distorted dNTP
    pools and impeded cell division, which falls hardest on the rapidly proliferating
    thymocyte compartment. This is the classical explanation for the immunodeficiency and
    the direct mechanistic parallel with adenosine deaminase deficiency, where accumulated
    dATP acts on the same enzyme.
  biological_processes:
  - preferred_term: DNA replication
    modifier: DECREASED
    term:
      id: GO:0006260
      label: DNA replication
  downstream:
  - target: Thymocyte and Peripheral T Lymphocyte Apoptosis
    causal_link_type: DIRECT
    description: >-
      Cells that cannot complete DNA replication in the proliferating thymocyte compartment
      die rather than mature.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The elevated dGTP found in PNP deficiency is thought to inhibit ribonucleotide
      reductase and, thus, impede cell division.
    explanation: >-
      States the ribonucleotide reductase mechanism and its consequence for cell division,
      which is the content of this node. The hedged wording of the source is preserved in
      the node description.

- name: Mitochondrial dGTP Accumulation and Impaired mtDNA Repair
  biological_scale: CELLULAR
  role: central_effector
  description: >-
    A distinct and more specific mechanism, established in PNP-knockout mice: dGTP
    accumulating within mitochondria inhibits mitochondrial DNA repair, so T cells become
    hypersensitive to the spontaneous mitochondrial DNA damage they would ordinarily
    tolerate. The knockout mice reproduce the human pattern - T lymphocytes affected more
    severely than B, impaired thymocyte differentiation, reduced peripheral T cells - and
    their T cells show increased apoptosis in vivo and heightened sensitivity to gamma
    irradiation in vitro. The irradiation-sensitivity phenotype is directly corroborated in
    human cells: lymphoblastoid B cells from a patient with absent PNP activity survived
    irradiation markedly less well than cells from partial-deficiency patients or healthy
    controls.
  biological_processes:
  - preferred_term: mitochondrial DNA repair
    modifier: DECREASED
    term:
      id: GO:0043504
      label: mitochondrial DNA repair
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  downstream:
  - target: Thymocyte and Peripheral T Lymphocyte Apoptosis
    causal_link_type: DIRECT
    description: >-
      Unrepaired mitochondrial DNA damage triggers apoptosis of the T cells that carry it.
  evidence:
  - reference: PMID:10859343
    reference_title: >-
      Mitochondrial basis for immune deficiency. Evidence from purine nucleoside
      phosphorylase-deficient mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We propose that the immune deficiency in PNP deficiency is a result of inhibition of
      mitochondrial DNA repair due to the accumulation of dGTP in the mitochondria.
    explanation: >-
      States the mitochondrial mechanism this node represents. Evidence source is
      MODEL_ORGANISM because the mechanism was established in PNP-knockout mice.
  - reference: PMID:10859343
    reference_title: >-
      Mitochondrial basis for immune deficiency. Evidence from purine nucleoside
      phosphorylase-deficient mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      T lymphocytes of PNP-deficient mice exhibit increased apoptosis in vivo and higher
      sensitivity to gamma irradiation in vitro.
    explanation: >-
      Supplies the apoptosis and DNA-damage-sensitivity phenotype that links this node to
      the downstream T-cell death node.
  - reference: PMID:32695102
    reference_title: >-
      Partial Purine Nucleoside Phosphorylase Deficiency Helps Determine Minimal Activity
      Required for Immune and Neurological Development.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The survival of lymphoblastoid B cells from 2 partial PNP-deficient patients after
      irradiation was similar to that of PNP-proficient cells and markedly higher than the
      survival of cells from a patient with absent PNP activity
    explanation: >-
      Human-cell corroboration that DNA-damage sensitivity tracks residual PNP activity,
      which is what makes the murine mitochondrial mechanism credible for human disease.

- name: Thymocyte and Peripheral T Lymphocyte Apoptosis
  biological_scale: CELLULAR
  role: central_effector
  description: >-
    Converging nuclear and mitochondrial DNA insults drive apoptosis of thymocytes and
    peripheral T cells. This is the point at which a metabolic lesion becomes an immune
    one, and it explains a clinical peculiarity of PNP deficiency: T-cell function may be
    normal at birth and decline with time, or fluctuate between low and normal, because the
    defect is a progressive attritional loss of cells rather than a developmental failure to
    make them.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  cell_types:
  - preferred_term: thymocyte
    term:
      id: CL:0000893
      label: thymocyte
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  downstream:
  - target: Impaired Thymocyte Development and Reduced T-Cell Output
    causal_link_type: DIRECT
    description: >-
      Loss of maturing thymocytes reduces the thymic production of peripheral T cells.
  evidence:
  - reference: PMID:10859343
    reference_title: >-
      Mitochondrial basis for immune deficiency. Evidence from purine nucleoside
      phosphorylase-deficient mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The end result is increased sensitivity of T cells to spontaneous mitochondrial DNA
      damage, leading to T cell depletion by apoptosis.
    explanation: >-
      States apoptotic T-cell depletion as the endpoint of the metabolic chain, the content
      of this node. Evidence source is MODEL_ORGANISM.
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      T-cell function may be profoundly deficient, may be normal at birth and then decrease
      with time, or may fluctuate repeatedly between low and normal.
    explanation: >-
      Documents the progressive and fluctuating T-cell course in patients, which is the
      clinical signature of attritional cell loss rather than a developmental block.

- name: Impaired Thymocyte Development and Reduced T-Cell Output
  biological_scale: TISSUE
  role: consequence
  description: >-
    The thymus fails as a T-cell factory: thymocyte differentiation is impaired and the
    numbers of maturing thymocytes and of peripheral T cells fall. Because the lesion is
    intrinsic to the haematopoietic compartment rather than to the thymic stroma, replacing
    the haematopoietic system corrects it - which is the mechanistic basis for
    transplantation being curative.
  cell_types:
  - preferred_term: thymocyte
    term:
      id: CL:0000893
      label: thymocyte
  downstream:
  - target: T-Cell Predominant Combined Immunodeficiency
    causal_link_type: DIRECT
    description: >-
      Loss of thymic output produces the peripheral T-cell deficiency that defines the
      clinical immunodeficiency.
  evidence:
  - reference: PMID:10859343
    reference_title: >-
      Mitochondrial basis for immune deficiency. Evidence from purine nucleoside
      phosphorylase-deficient mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      PNP knockout mice exhibit impaired thymocyte differentiation, reduced mitogenic and
      allogeneic responses, and decreased numbers of maturing thymocytes and peripheral T
      cells.
    explanation: >-
      Documents impaired thymocyte differentiation and reduced thymic output, the content of
      this node. Evidence source is MODEL_ORGANISM.

- name: CNS Purine Nucleotide Imbalance
  biological_scale: MOLECULAR
  role: modifier
  description: >-
    Purine imbalance extends to the central nervous system, and depressed GTP levels have
    been proposed to correlate with the neurological dysfunction. This node is deliberately
    curated as a proposal rather than an established chain: the mechanism connecting purine
    imbalance to neuronal dysfunction in PNP deficiency is not settled, the neurological arm
    is not explained by the T-cell mechanism, and transplantation corrects the immune defect
    without reliably reversing established neurological disease. See the
    `pnp-neurological-mechanism` knowledge gap.
  downstream:
  - target: Neurological Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The intermediates between CNS purine imbalance and neuronal dysfunction are not
      established; the edge is asserted at low confidence and flagged as an open gap.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Depressed GTP levels may correlate with neurologic dysfunction.
    explanation: >-
      The only mechanistic proposal available for the neurological arm, and the source
      itself states it only as a possible correlation. Recorded as PARTIAL for that reason.

- name: T-Cell Predominant Combined Immunodeficiency
  biological_scale: ORGANISM
  role: consequence
  description: >-
    The resulting immunodeficiency is combined but asymmetric: T-cell numbers and function
    are profoundly affected while B-cell function is normal in most patients and deficient
    in roughly a third, and NK function is variable. Serum immunoglobulins are often normal
    or only slightly reduced, which is a diagnostic trap - normal immunoglobulins do not
    exclude the disease. PNP deficiency accounts for approximately 4% of severe combined
    immunodeficiency.
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  downstream:
  - target: Recurrent and Opportunistic Infection
    causal_link_type: DIRECT
    description: >-
      Loss of T-cell immunity permits recurrent bacterial and opportunistic infection.
  - target: Immune Dysregulation with Autoimmunity and EBV-Driven Lymphoma
    causal_link_type: DIRECT
    description: >-
      Defective T-cell regulation and surveillance permit autoimmunity and uncontrolled
      EBV-driven lymphoproliferation.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      B-cell function can be normal but is deficient in approximately one third of patients.
    explanation: >-
      Quantifies the asymmetry between the T-cell and B-cell arms that defines this node.
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Purine nucleoside phosphorylase (PNP) deficiency is a rare inherited disease
      accounting for approximately 4% of patients with severe combined immunodeficiency.
    explanation: >-
      Places the disease quantitatively within the SCID population.

- name: Recurrent and Opportunistic Infection
  biological_scale: ORGANISM
  role: consequence
  description: >-
    Recurrent respiratory and gastrointestinal infections, usually beginning in the first
    year of life, and opportunistic infections reflecting the T-cell defect. Infection is
    the commonest cause of death: in one four-patient series three died of sepsis during
    follow-up.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PNP-deficient patients suffer from recurrent infections, usually beginning in the
      first year of life.
    explanation: >-
      Establishes recurrent infection and its typical age of onset.
  - reference: PMID:33061764
    reference_title: >-
      Recurrent infections, neurologic signs, low serum uric acid levels, and lymphopenia in
      childhood: Purine nucleoside phosphorylase deficiency, an emergency for infants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three of the four patients were lost due to sepsis during follow-up, and one patient
      was lost due to veno-occlusive disease in the post-hematopoietic stem cell
      transplantation period.
    explanation: >-
      Documents infection as the dominant cause of death in an untransplanted cohort, the
      basis for treating the condition as a paediatric emergency.

- name: Immune Dysregulation with Autoimmunity and EBV-Driven Lymphoma
  biological_scale: ORGANISM
  role: consequence
  description: >-
    Loss of T-cell regulation and surveillance produces two distinct complications.
    Autoimmunity affects about a third of patients, most often autoimmune haemolytic
    anaemia, with immune thrombocytopenic purpura and lupus also reported. Separately,
    failure of T-cell control of Epstein-Barr virus permits EBV-associated lymphoma, which
    has repeatedly proved fatal before transplantation could be undertaken - a specific
    reason the diagnosis is urgent rather than merely serious.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One third of patients develop autoimmune disease. The most common manifestation of
      this is autoimmune hemolytic anemia.
    explanation: >-
      Quantifies the autoimmune arm and names its commonest manifestation.
  - reference: PMID:31707514
    reference_title: The Broad Clinical Spectrum and Transplant Results of PNP Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One patient died of EBV-related lymphoma with CNS involvement prior to transplant.
    explanation: >-
      Documents fatal EBV-driven lymphoma occurring before transplantation, the specific
      malignancy risk of this node.

- name: Neurological Dysfunction
  biological_scale: ORGANISM
  role: consequence
  description: >-
    About two thirds of patients have neurological disease, ranging from spasticity through
    developmental delay to intellectual disability, and roughly a quarter first come to
    medical attention for neurological rather than infectious problems. The neurological arm
    is mechanistically separate from the immunological one: it is not explained by T-cell
    depletion, it is absent in some patients with full-blown immunodeficiency, and it is not
    reliably reversed by correcting the immune defect. Reported post-transplant neurological
    outcomes range from excellent to persistent mild developmental delay without further
    deterioration.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two thirds of patients have evidence of neurologic disorders. Findings range from
      spasticity to developmental delay, to mental retardation.
    explanation: >-
      Quantifies the neurological arm and describes its range, the content of this node.
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients usually present with infections but approximately one fourth have come to
      medical care initially for neurological problems.
    explanation: >-
      Shows the neurological arm can be the presenting problem, supporting its status as a
      partly independent disease dimension.
  - reference: PMID:30885031
    reference_title: >-
      The First Purine Nucleoside Phosphorylase Deficiency Patient Resembling IgA Deficiency
      and a Review of the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PNP deficiency should be considered in late-onset children with recurrent infections,
      autoimmune disorders without typical neurologic impairment.
    explanation: >-
      Documents a patient with full immunodeficiency and autoimmunity but no neurological
      dysfunction. Recorded as PARTIAL because it qualifies the neurological arm as
      non-obligate rather than supporting it.

- name: Unrestrained TLR7 Signalling by Guanosine Nucleoside Ligands
  biological_scale: MOLECULAR
  role: central_effector
  description: >-
    This node resolves what would otherwise be the central paradox of the disease: how a
    profound T-cell immunodeficiency produces autoimmunity in a third of patients. PNP does
    not have one immunological job but two, in different lineages. In B lymphocytes and
    macrophages it controls the levels of the (deoxy)guanosine nucleosides that are the
    ligands of Toll-like receptor 7, so losing PNP removes a brake on innate nucleic-acid
    sensing. Overriding that brake drives germinal centre formation in the absence of any
    exogenous antigen and accelerates disease in a mouse autoimmunity model. Autoimmunity in
    PNP deficiency is therefore not merely the passive consequence of failed T-cell
    regulation - it has its own positive, lineage-specific mechanism running in parallel.
  biological_processes:
  - preferred_term: toll-like receptor 7 signaling pathway
    modifier: INCREASED
    term:
      id: GO:0034154
      label: toll-like receptor 7 signaling pathway
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  downstream:
  - target: Immune Dysregulation with Autoimmunity and EBV-Driven Lymphoma
    causal_link_type: DIRECT
    description: >-
      Unrestrained TLR7 signalling drives antigen-independent germinal centre formation and
      accelerates autoimmune disease.
  evidence:
  - reference: PMID:35653193
    reference_title: >-
      Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell
      immunodeficiency and TLR7-associated autoimmunity.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In B lymphocytes and macrophages, PNP regulates Toll-like receptor 7 signaling by
      controlling the levels of its (deoxy)guanosine nucleoside ligands.
    explanation: >-
      Establishes the lineage-specific TLR7 checkpoint that this node represents. Evidence
      source is MODEL_ORGANISM because the mechanism was established in mouse and cellular
      systems.
  - reference: PMID:35653193
    reference_title: >-
      Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell
      immunodeficiency and TLR7-associated autoimmunity.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Overriding this regulatory mechanism promotes germinal center formation in the absence
      of exogenous antigen and accelerates disease in a mouse model of autoimmunity.
    explanation: >-
      Supplies the causal consequence of losing the TLR7 brake, which justifies the downstream
      edge to the immune-dysregulation node. Evidence source is MODEL_ORGANISM.
  - reference: PMID:35653193
    reference_title: >-
      Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell
      immunodeficiency and TLR7-associated autoimmunity.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      This work reveals that one purine metabolism gene protects against immunodeficiency and
      autoimmunity via independent mechanisms operating in distinct immune lineages
    explanation: >-
      States explicitly that the immunodeficiency and autoimmunity arms are independent
      lineage-specific mechanisms, which is why they are modelled here as parallel branches
      rather than one causing the other.

- name: SAMHD1-Dependent Synthetic Lethality in Developing T Cells
  biological_scale: MOLECULAR
  role: modifier
  description: >-
    The T-cell arm is not simply dGTP toxicity but a gene-interaction effect. During T-cell
    development, PNP inactivation is synthetically lethal with downregulation of the dNTP
    triphosphohydrolase SAMHD1 - the enzyme that would otherwise dispose of excess dNTPs.
    Developing thymocytes physiologically downregulate SAMHD1, so they lose the very
    safeguard that would protect them from an accumulating dNTP load, which is a second and
    more specific explanation for why the disease targets the developing T-cell compartment.
    The interaction requires deoxycytidine kinase activity and is antagonised by
    microenvironmental deoxycytidine, so it is in principle a modifiable dependency.
  cell_types:
  - preferred_term: thymocyte
    term:
      id: CL:0000893
      label: thymocyte
  downstream:
  - target: Thymocyte and Peripheral T Lymphocyte Apoptosis
    causal_link_type: DIRECT
    description: >-
      Loss of the SAMHD1 safeguard during T-cell development converts the dNTP burden into
      lethality for the developing thymocyte.
  evidence:
  - reference: PMID:35653193
    reference_title: >-
      Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell
      immunodeficiency and TLR7-associated autoimmunity.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      During T cell development, PNP inactivation is synthetically lethal with downregulation
      of the dNTP triphosphohydrolase SAMHD1.
    explanation: >-
      Establishes the synthetic-lethal gene interaction that gives the T-cell arm its
      developmental-stage specificity. Evidence source is MODEL_ORGANISM.
  - reference: PMID:35653193
    reference_title: >-
      Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell
      immunodeficiency and TLR7-associated autoimmunity.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      This interaction requires deoxycytidine kinase activity and is antagonized by
      microenvironmental deoxycytidine.
    explanation: >-
      Identifies the kinase required for the toxic conversion and a microenvironmental
      antagonist, which is why the interaction is described here as potentially modifiable.

phenotypes:
- category: Clinical
  name: Combined immunodeficiency
  description: >-
    Combined T- and B-cell immunodeficiency with T cells affected disproportionately.
    PNP deficiency accounts for approximately 4% of severe combined immunodeficiency.
  phenotype_term:
    preferred_term: Combined immunodeficiency
    term:
      id: HP:0005387
      label: Combined immunodeficiency
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In PNP deficiency, T- and B-cell immunity are affected.
    explanation: >-
      Establishes the combined character of the immunodeficiency.

- category: Clinical
  name: Recurrent infections
  description: >-
    Recurrent bacterial and opportunistic infections beginning in the first year of life,
    dominated by respiratory and gastrointestinal disease, and the commonest cause of
    death.
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
    temporality: RECURRENT
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PNP-deficient patients suffer from recurrent infections, usually beginning in the
      first year of life.
    explanation: >-
      Establishes recurrent infection and its typical onset.

- category: Laboratory
  name: Decreased total T cell count
  description: >-
    Profound T-cell lymphopenia is the defining laboratory abnormality. Because the
    mechanism is attritional apoptosis rather than a developmental block, counts may be
    normal at birth and fall over time, or fluctuate - so a single normal result does not
    exclude the diagnosis.
  phenotype_term:
    preferred_term: Decreased total T cell count
    term:
      id: HP:0005403
      label: Decreased total T cell count
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:30885031
    reference_title: >-
      The First Purine Nucleoside Phosphorylase Deficiency Patient Resembling IgA Deficiency
      and a Review of the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a rare autosomal recessive primary immunodeficiency disorder characterized by
      decreased numbers of T-cells, variable B-cell abnormalities, decreased amount of serum
      uric acid and PNP enzyme activity
    explanation: >-
      Names decreased T-cell numbers as a defining feature of the disorder.
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      T-cell function may be profoundly deficient, may be normal at birth and then decrease
      with time, or may fluctuate repeatedly between low and normal.
    explanation: >-
      Documents the progressive and fluctuating course that makes a single normal T-cell
      result non-exclusionary.

- category: Laboratory
  name: Hypouricemia
  description: >-
    Low serum uric acid, the direct biochemical consequence of interrupting the purine
    catabolic route to urate, and the cheapest available diagnostic clue in a lymphopenic
    infant. Not universal: patients with partial deficiency had normal blood uric acid while
    still excreting increased PNP substrates in urine.
  phenotype_term:
    preferred_term: Hypouricemia
    term:
      id: HP:0003537
      label: Hypouricemia
  evidence:
  - reference: PMID:33061764
    reference_title: >-
      Recurrent infections, neurologic signs, low serum uric acid levels, and lymphopenia in
      childhood: Purine nucleoside phosphorylase deficiency, an emergency for infants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Absolute lymphocyte counts and serum uric acid levels were very low, and serum
      immunoglobulin levels were normal or slightly lower in all cases.
    explanation: >-
      Documents low serum uric acid in all four cases of a confirmed case series, alongside
      the deceptively normal immunoglobulins.

- category: Neurologic
  name: Global developmental delay
  frequency: FREQUENT
  description: >-
    Developmental delay is one of the three characteristic neurological manifestations, the
    others being spasticity and intellectual disability, each curated separately. The FREQUENT
    band comes from the two-thirds figure for neurological disease as a whole rather than for
    developmental delay specifically, since the source reports the neurological arm as a single
    proportion - so the band is an upper bound for this individual manifestation. About a
    quarter of patients present neurologically rather than with infection. This arm is not
    explained by the T-cell mechanism and is not reliably reversed by transplantation.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two thirds of patients have evidence of neurologic disorders. Findings range from
      spasticity to developmental delay, to mental retardation.
    explanation: >-
      Two thirds is approximately 67%, which falls in the FREQUENT band (30-79%) and is the
      quantitative basis for the frequency asserted here.

- category: Neurologic
  name: Spasticity
  description: >-
    Increased muscle tone with hypertonia, one of the characteristic neurological findings
    and sometimes the presenting feature.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Findings range from spasticity to developmental delay, to mental retardation.
    explanation: >-
      Names spasticity as part of the neurological spectrum.
  - reference: PMID:39772979
    reference_title: >-
      Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency
      with two novel mutations: a case report and review of literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the case of a 6-year-old boy who presented with muscular hypertonia,
      impaired growth, and recurrent infections
    explanation: >-
      Documents hypertonia as a presenting feature in a genetically confirmed patient.

- category: Clinical
  name: Autoimmunity
  frequency: FREQUENT
  description: >-
    Autoimmune disease develops in about a third of patients, placing it at the lower edge of
    the FREQUENT band (30-79%). Autoimmune haemolytic anaemia is the commonest manifestation;
    immune thrombocytopenic purpura and systemic lupus erythematosus are also reported.
  phenotype_term:
    preferred_term: Autoimmunity
    term:
      id: HP:0002960
      label: Autoimmunity
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One third of patients develop autoimmune disease. The most common manifestation of this
      is autoimmune hemolytic anemia.
    explanation: >-
      One third is approximately 33%, at the lower edge of the FREQUENT band (30-79%), and is
      the quantitative basis for the frequency asserted here.

- category: Clinical
  name: Autoimmune hemolytic anemia
  description: >-
    The commonest autoimmune manifestation of PNP deficiency, reflecting loss of T-cell
    regulatory control rather than any direct effect of purine toxicity on erythrocytes.
  phenotype_term:
    preferred_term: Autoimmune hemolytic anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One third of patients develop autoimmune disease. The most common manifestation of this
      is autoimmune hemolytic anemia.
    explanation: >-
      Names autoimmune haemolytic anaemia as the commonest autoimmune manifestation.

- category: Clinical
  name: Failure to thrive
  description: >-
    Impaired growth accompanying recurrent infection and chronic illness.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:35063692
    reference_title: >-
      Combined immunodeficiency due to purine nucleoside phosphorylase deficiency: Outcome of
      three patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They present clinically with recurrent infections, failure to thrive, various
      neurological disorders, malignancies, and autoimmune diseases.
    explanation: >-
      Lists failure to thrive among the presenting clinical features.

- category: Neurologic
  name: Ataxia
  description: >-
    Incoordination, reported among the frequently observed neurological findings in PNP
    deficiency. It has a plausible structural correlate in the same source: cranial MRI shows
    cerebellar as well as cerebral cortical atrophy, so the ataxia is not an isolated symptom
    but tracks documented cerebellar loss.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:33061764
    reference_title: >-
      Recurrent infections, neurologic signs, low serum uric acid levels, and lymphopenia in
      childhood: Purine nucleoside phosphorylase deficiency, an emergency for infants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Developmental retardation, hypertonia, spasticity, tremors, ataxia, and motor retardation
      are observed frequently.
    explanation: >-
      Names ataxia directly among the neurological findings frequently observed in patients
      with PNP deficiency.
  - reference: PMID:33061764
    reference_title: >-
      Recurrent infections, neurologic signs, low serum uric acid levels, and lymphopenia in
      childhood: Purine nucleoside phosphorylase deficiency, an emergency for infants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cranial MRI reveals cerebral cortical and cerebellar atrophy and white matter
      demyelination
    explanation: >-
      Supplies the cerebellar structural correlate that makes ataxia a coherent finding rather
      than an isolated symptom report.

- category: Neurologic
  name: Hypertonia
  description: >-
    Increased muscle tone, reported frequently alongside spasticity. Recorded separately from
    spasticity because the sources list them as distinct observations.
  phenotype_term:
    preferred_term: Hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
  evidence:
  - reference: PMID:33061764
    reference_title: >-
      Recurrent infections, neurologic signs, low serum uric acid levels, and lymphopenia in
      childhood: Purine nucleoside phosphorylase deficiency, an emergency for infants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Developmental retardation, hypertonia, spasticity, tremors, ataxia, and motor retardation
      are observed frequently.
    explanation: >-
      Names hypertonia among the frequently observed neurological findings.
  - reference: PMID:39772979
    reference_title: >-
      Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency
      with two novel mutations: a case report and review of literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the case of a 6-year-old boy who presented with muscular hypertonia, impaired
      growth, and recurrent infections
    explanation: >-
      Documents hypertonia as a presenting feature in a genetically confirmed patient.

- category: Neurologic
  name: Tremor
  description: >-
    Tremor, listed among the frequently observed neurological findings.
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:33061764
    reference_title: >-
      Recurrent infections, neurologic signs, low serum uric acid levels, and lymphopenia in
      childhood: Purine nucleoside phosphorylase deficiency, an emergency for infants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Developmental retardation, hypertonia, spasticity, tremors, ataxia, and motor retardation
      are observed frequently.
    explanation: >-
      Names tremor among the frequently observed neurological findings.

- category: Neurologic
  name: Cerebellar atrophy
  description: >-
    Cerebellar and cerebral cortical atrophy with white matter demyelination on cranial MRI -
    the structural counterpart of the clinical neurological arm, and evidence that the CNS
    involvement is degenerative rather than purely functional.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: PMID:33061764
    reference_title: >-
      Recurrent infections, neurologic signs, low serum uric acid levels, and lymphopenia in
      childhood: Purine nucleoside phosphorylase deficiency, an emergency for infants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cranial MRI reveals cerebral cortical and cerebellar atrophy and white matter
      demyelination
    explanation: >-
      Documents the imaging findings, including cerebellar atrophy, in PNP deficiency.

- category: Clinical
  name: Lymphoma
  description: >-
    EBV-driven lymphoma arising from failed T-cell control of the virus. Curated as a phenotype
    as well as a pathophysiology consequence because it is the specific malignancy that has
    repeatedly proved fatal before transplantation could be undertaken, and so belongs in the
    phenotype view a clinician reads.
  phenotype_term:
    preferred_term: Lymphoma
    term:
      id: HP:0002665
      label: Lymphoma
  evidence:
  - reference: PMID:31707514
    reference_title: The Broad Clinical Spectrum and Transplant Results of PNP Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One patient died of EBV-related lymphoma with CNS involvement prior to transplant.
    explanation: >-
      Documents fatal EBV-driven lymphoma in a patient with PNP deficiency.
  - reference: PMID:35063692
    reference_title: >-
      Combined immunodeficiency due to purine nucleoside phosphorylase deficiency: Outcome of
      three patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One patient died prior to HSCT due to EBV-associated lymphoma.
    explanation: >-
      A second independent series reporting fatal EBV-associated lymphoma before
      transplantation.

- category: Neurologic
  name: Intellectual disability
  description: >-
    Cognitive impairment at the more severe end of the neurological spectrum, described in the
    classic case series alongside spasticity and developmental delay.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Findings range from spasticity to developmental delay, to mental retardation.
    explanation: >-
      Names the most severe cognitive endpoint of the neurological spectrum. The source's
      historical terminology is quoted verbatim as required; the curated term uses current
      HPO nomenclature.

diagnosis:
- name: Purine nucleoside phosphorylase enzyme activity assay
  description: >-
    Demonstration of absent or severely reduced PNP catalytic activity, conventionally
    measured by conversion of labelled inosine in erythrocyte haemolysates, mononuclear cells
    or lymphoblastoid cells, is the confirmatory biochemical test. Quantitation rather than a
    simple present/absent result matters here, because residual activity predicts phenotype:
    8-11% of normal was compatible with survival into the third decade and normal
    neurological development.
  diagnosis_term:
    preferred_term: enzyme activity assay
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  results: >-
    Absent or severely reduced PNP activity confirms the diagnosis; residual activity should be
    quantified because it predicts severity.
  evidence:
  - reference: PMID:32695102
    reference_title: >-
      Partial Purine Nucleoside Phosphorylase Deficiency Helps Determine Minimal Activity
      Required for Immune and Neurological Development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PNP protein expression was determined by Western Blotting in lymphoblastoid B cells. DNA
      repair was quantified by measuring viability of lymphoblastoid B cells following ionizing
      irradiation.
    explanation: >-
      Describes the specimen types and the paired protein-expression and DNA-repair assays used
      to characterise PNP deficiency, complementing the catalytic-activity measurement.
  - reference: PMID:30885031
    reference_title: >-
      The First Purine Nucleoside Phosphorylase Deficiency Patient Resembling IgA Deficiency
      and a Review of the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      characterized by decreased numbers of T-cells, variable B-cell abnormalities, decreased
      amount of serum uric acid and PNP enzyme activity
    explanation: >-
      Names reduced PNP enzyme activity, alongside T-cell depletion and low uric acid, as a
      defining diagnostic feature.

- name: Plasma and urine purine metabolite profiling
  description: >-
    Quantitation of inosine, deoxyinosine, guanosine and deoxyguanosine with serum uric acid.
    The characteristic pattern is raised PNP substrates with low urate. The urinary substrate
    elevation is the more sensitive half of the pair: in partial deficiency blood uric acid was
    entirely normal while urinary PNP substrates were still raised, so a normal urate does not
    exclude the diagnosis.
  diagnosis_term:
    preferred_term: metabolite profiling
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  results: >-
    Elevated inosine, guanosine, deoxyinosine and deoxyguanosine in plasma and urine with low
    serum uric acid.
  evidence:
  - reference: PMID:24767876
    reference_title: >-
      Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using
      tandem mass spectrometry on dried blood spots.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      caused by a enzyme defect leading to the accumulation of inosine, 2'-deoxy-inosine
      (dIno), guanosine, and 2'-deoxy-guanosine (dGuo) in all cells, especially lymphocytes
    explanation: >-
      Names the four accumulating metabolites that constitute the diagnostic profile.
  - reference: PMID:32695102
    reference_title: >-
      Partial Purine Nucleoside Phosphorylase Deficiency Helps Determine Minimal Activity
      Required for Immune and Neurological Development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All siblings had normal blood uric acid and increased PNP substrates in the urine.
    explanation: >-
      Demonstrates that urinary substrate elevation persists when serum urate is normal, which
      is why urate alone is an inadequate screen.

- name: Lymphocyte subset enumeration and immune function testing
  description: >-
    T, B and NK cell counts with immunoglobulins and proliferation responses. Two traps are
    worth recording. Serum immunoglobulins are frequently normal or only slightly reduced, so
    normal immunoglobulins do not exclude the diagnosis. And T-cell counts may be normal at
    birth and decline with time or fluctuate, because the defect is progressive attritional
    apoptosis rather than a developmental block - so a single normal result is not
    exclusionary either.
  diagnosis_term:
    preferred_term: immunophenotyping
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  results: >-
    Reduced T-cell numbers with variable B and NK abnormalities; immunoglobulins may be normal.
  evidence:
  - reference: PMID:33061764
    reference_title: >-
      Recurrent infections, neurologic signs, low serum uric acid levels, and lymphopenia in
      childhood: Purine nucleoside phosphorylase deficiency, an emergency for infants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Absolute lymphocyte counts and serum uric acid levels were very low, and serum
      immunoglobulin levels were normal or slightly lower in all cases.
    explanation: >-
      Documents the lymphopenia-with-normal-immunoglobulins pattern that makes this a
      diagnostic trap.

- name: PNP gene sequencing with deletion and duplication analysis
  description: >-
    Confirmation of biallelic pathogenic PNP variants. Sequencing alone is insufficient: the
    reported allelic spectrum includes multi-exon deletions as well as point and frameshift
    variants, so copy-number analysis has to accompany sequence analysis or a second allele can
    be missed. Whole-exome sequencing has been the route to diagnosis in several reported
    atypical presentations.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  results: >-
    Two pathogenic PNP alleles confirm the diagnosis; deletion/duplication analysis is required
    alongside sequencing.
  evidence:
  - reference: PMID:39772979
    reference_title: >-
      Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency
      with two novel mutations: a case report and review of literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One hemizygous variant was c.385dup (p.Ile129Asnfs*6) in exon 4. The other was a
      heterozygous deletion in exon 2-6.
    explanation: >-
      A compound genotype pairing a frameshift with a multi-exon deletion, which is exactly the
      case sequencing alone would fail to resolve.
  - reference: PMID:30885031
    reference_title: >-
      The First Purine Nucleoside Phosphorylase Deficiency Patient Resembling IgA Deficiency
      and a Review of the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this study, whole-exome sequencing was used to detect mutation in the case suspected
      of having primary immunodeficiency.
    explanation: >-
      Documents whole-exome sequencing as the diagnostic route in an atypical presentation.

- name: Newborn screening by TREC/KREC and dried-blood-spot tandem mass spectrometry
  description: >-
    Two complementary newborn-screening routes exist and the distinction matters. Tandem mass
    spectrometry on dried blood spots detects the purine metabolite signature directly and was
    the original route; TREC/KREC analysis detects the downstream T-cell lymphopenia and can
    also pick the disease up, as first reported in 2021. Because transplantation is curative
    but its success depends on being early - and because EBV-driven lymphoma before transplant
    is a documented cause of death - presymptomatic detection is unusually consequential here.
    A TREC-based screen may still miss milder or evolving disease, since it detects the
    consequence rather than the metabolic defect.
  diagnosis_term:
    preferred_term: newborn screening
    term:
      id: NCIT:C81178
      label: Newborn Screening
  results: >-
    Reduced TREC/KREC copy number and/or an abnormal dried-blood-spot purine profile prompt
    confirmatory enzyme and molecular testing.
  evidence:
  - reference: PMID:24767876
    reference_title: >-
      Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using
      tandem mass spectrometry on dried blood spots.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatments are available and curative for PNP deficiency, but their efficacy depends on
      the early approach. PNP-combined immunodeficiency complies with the criteria for
      inclusion in a newborn screening program.
    explanation: >-
      States the rationale for newborn screening - a curative treatment whose success is
      time-dependent - and the mass-spectrometry route.
  - reference: PMID:34698070
    reference_title: >-
      Early Diagnosis and Treatment of Purine Nucleoside Phosphorylase (PNP) Deficiency through
      TREC-Based Newborn Screening.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To date, PNP deficiency has been detected in newborn screening only through the use of
      liquid chromatography tandem mass spectrometry. We report the first case in which PNP
      deficiency was detected by TREC analysis.
    explanation: >-
      Documents the TREC route as a second, later-established screening modality distinct from
      mass spectrometry.
  - reference: PMID:40981309
    reference_title: >-
      The Success of Newborn Screening Beyond War: An International Collaborative Case of Purine
      Nucleoside Phosphorylase (PNP) Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ukraine successfully carried out NBS on a neonatal dried blood spot (DBS) by real-time
      PCR, which showed remarkably reduced T-cell receptor and kappa-deleting recombination
      excision circles (TREC/KREC).
    explanation: >-
      A worked case of TREC/KREC screening detecting PNP deficiency and leading to successful
      transplantation, demonstrating the screening-to-cure pathway in practice.

clinical_trials:
- name: NCT06092346
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >-
    An NIH prospective observational natural-history protocol covering disorders of pyrimidine
    and purine metabolism, of which PNP deficiency is one. Observational rather than
    interventional, and relevant because the entry's principal knowledge gap - the mechanism and
    time course of the neurological arm - is exactly the kind of question a natural-history
    cohort with systematic phenotyping is positioned to answer.
  target_phenotypes:
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  - preferred_term: Combined immunodeficiency
    term:
      id: HP:0005387
      label: Combined immunodeficiency
  evidence:
  - reference: clinicaltrials:NCT06092346
    reference_title: "Prospective Study of the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DPPMs can cause dysfunctions throughout the body, especially in the brain, blood, kidneys,
      and immune system.
    explanation: >-
      States the scope of the natural-history protocol, covering the neurological and immune
      dimensions that are this entry's two disease arms.

treatments:
- name: Allogeneic haematopoietic stem cell transplantation
  description: >-
    The only available cure. Replacing the patient's haematopoietic system with
    PNP-competent donor cells restores enzyme activity in the lymphoid compartment where
    the substrate burden is greatest, giving durable immune reconstitution. Reported
    outcomes are good when transplantation is performed in time - three of four patients in
    one Israeli series achieved good immune reconstitution over 8 to 108 months of
    follow-up with excellent neurological outcomes - but the qualifier matters: the fourth
    patient died of EBV-related lymphoma before transplant, and in a Turkish series a
    patient was lost to veno-occlusive disease after transplant. Neurological disease
    already established is not reliably reversed, though post-transplant series report no
    further deterioration.
  treatment_term:
    preferred_term: Hematopoietic Cell Transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  therapeutic_modality: CELL_THERAPY
  target_mechanisms:
  - target: Loss of Purine Nucleoside Phosphorolysis
    treatment_effect: INHIBITS
    description: >-
      Donor-derived haematopoiesis supplies PNP-competent cells to the lymphoid compartment,
      restoring the missing phosphorolysis step where the substrate burden is greatest. This is
      why the therapeutic logic is metabolic rather than merely immunological, and why
      replacing the haematopoietic compartment suffices: the enzymatic lesion that matters is
      intrinsic to it. The partial-deficiency data suggest the bar is low, since 8-11% of normal
      activity supported near-normal immunity.
  - target: Impaired Thymocyte Development and Reduced T-Cell Output
    treatment_effect: INHIBITS
    description: >-
      Restoring enzyme-competent haematopoiesis re-establishes thymocyte development and
      peripheral T-cell output. Neurological disease already established at the time of
      transplant is not reliably reversed, which is the principal limit of the approach.
  - target: T-Cell Predominant Combined Immunodeficiency
    treatment_effect: INHIBITS
    description: >-
      Restoring enzyme-competent T-cell development corrects the combined immunodeficiency.
  evidence:
  - reference: PMID:35063692
    reference_title: >-
      Combined immunodeficiency due to purine nucleoside phosphorylase deficiency: Outcome of
      three patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hematopoietic stem cell transplantation (HSCT) is the only available cure for patients
      with PNP deficiency.
    explanation: >-
      Establishes transplantation as the only curative option.
  - reference: PMID:31707514
    reference_title: The Broad Clinical Spectrum and Transplant Results of PNP Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HSCT offers a good treatment option, with excellent clinical outcomes, when preformed in
      a timely manner.
    explanation: >-
      Supports transplantation with the timing qualifier that governs its success.
  - reference: PMID:35063692
    reference_title: >-
      Combined immunodeficiency due to purine nucleoside phosphorylase deficiency: Outcome of
      three patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Over the course of post-HSCT, there was no further aggravation of the patients'
      neurological symptoms. Although both of the patients still had mild developmental delay,
      new developmental milestones were achieved.
    explanation: >-
      Documents that transplantation halts but does not reverse established neurological
      disease. Recorded as PARTIAL because it both supports the treatment and bounds what it
      achieves.

- name: Supportive care and infection prophylaxis
  description: >-
    Immunoglobulin replacement, antimicrobial prophylaxis and irradiated, CMV-safe blood
    products bridge the patient to transplantation. This is explicitly a bridge and not a
    treatment of the disease: no supportive or dietary approach has been consistently
    successful, and the older attempts - red cell transfusion to supply enzyme, dietary
    purine and pyrimidine supplementation - did not work.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  therapeutic_modality: OTHER
  target_mechanisms:
  - target: Recurrent and Opportunistic Infection
    treatment_effect: INHIBITS
    description: >-
      Prophylaxis and immunoglobulin replacement reduce the infection burden without altering
      the underlying enzyme defect.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Many different therapies have been utilized for PNP deficiency including bone marrow
      transplantation, red cell transfusions, and supplementation of the diet with purines and
      pyrimidines. None of these therapies has been consistently successful.
    explanation: >-
      Documents the historical failure of non-transplant approaches. Recorded as PARTIAL
      because it establishes what supportive care cannot do rather than supporting an
      effective therapy; note the review predates modern transplant outcomes, which are
      curated separately above.

animal_models:
- name: PNP-knockout mouse
  species: Mouse
  genotype: Pnp-deficient (knockout)
  publication: PMID:10859343
  description: >-
    Purpose-built to interrogate the mechanism of the human immunodeficiency, and the source of
    the mitochondrial hypothesis this entry curates. It reproduces the defining asymmetry of
    the human disease - T lymphocytes affected more severely than B - with impaired thymocyte
    differentiation, reduced mitogenic and allogeneic responses, and decreased numbers of
    maturing thymocytes and peripheral T cells.
  modeled_mechanisms:
  - target: Mitochondrial dGTP Accumulation and Impaired mtDNA Repair
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      The model is where this mechanism was established: mitochondrial dGTP accumulation
      inhibiting mtDNA repair, leaving T cells hypersensitive to spontaneous mitochondrial DNA
      damage.
    limitations: >-
      The mechanism is proposed from the murine phenotype and has not been demonstrated
      directly in human PNP-deficient tissue. The nearest human corroboration is indirect -
      irradiation survival of patient lymphoblastoid B cells tracking residual PNP activity -
      which supports DNA-damage hypersensitivity without confirming the mitochondrial locus.
      Notably, an independent PNP-deficient mouse line failed to show dGTP accumulation in
      thymocytes or spleen leucocytes at all, and instead had a secondary deficiency of
      deoxyguanosine kinase, so the murine metabolic phenotype is not uniform across lines.
    readouts:
    - name: T lymphocyte apoptosis and gamma-irradiation sensitivity
      target: Mitochondrial dGTP Accumulation and Impaired mtDNA Repair
      direction: INCREASED
      interpretation: >-
        Increased apoptosis in vivo with heightened sensitivity to DNA damage in vitro is the
        functional signature of impaired repair capacity.
      evidence:
      - reference: PMID:10859343
        reference_title: "Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          T lymphocytes of PNP-deficient mice exhibit increased apoptosis in vivo and higher
          sensitivity to gamma irradiation in vitro.
        explanation: >-
          Reports the apoptosis and DNA-damage-sensitivity measurements underpinning this node.
    evidence:
    - reference: PMID:10859343
      reference_title: "Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We propose that the immune deficiency in PNP deficiency is a result of inhibition of
        mitochondrial DNA repair due to the accumulation of dGTP in the mitochondria.
      explanation: >-
        Supports treating this model as the source of, and evidence for, the mitochondrial node.

  - target: Impaired Thymocyte Development and Reduced T-Cell Output
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      The model reproduces the human thymic phenotype closely: impaired thymocyte
      differentiation with reduced numbers of maturing thymocytes and peripheral T cells.
    limitations: >-
      Murine and human thymic development differ in tempo and in the duration of thymic output,
      so the timing of decline is not directly transferable; the model also does not reproduce
      the fluctuating T-cell counts described in patients.
    readouts:
    - name: Maturing thymocyte and peripheral T-cell numbers
      target: Impaired Thymocyte Development and Reduced T-Cell Output
      direction: DECREASED
      interpretation: >-
        Reduced thymocyte and peripheral T-cell numbers are the direct measurement of failed
        thymic output.
      evidence:
      - reference: PMID:10859343
        reference_title: "Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          PNP knockout mice exhibit impaired thymocyte differentiation, reduced mitogenic and
          allogeneic responses, and decreased numbers of maturing thymocytes and peripheral T
          cells.
        explanation: >-
          Reports the thymocyte and peripheral T-cell measurements for this node.
    evidence:
    - reference: PMID:10859343
      reference_title: "Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Similar to the human disease, PNP deficiency in mice causes an immunodeficiency that
        affects T lymphocytes more severely than B lymphocytes.
      explanation: >-
        States the correspondence with the human disease that justifies treating this model as
        informative for the thymic node.


- name: B6-NPE / B6-NPF ENU-induced PNP-deficient mouse strains
  species: Mouse
  genotype: >-
    Pnp hypomorphic ENU-induced point mutants (B6-NPE, B6-NPF); residual PNP activity with a
    secondary deficiency of deoxyguanosine kinase
  publication: PMID:7918681
  description: >-
    Chemically induced hypomorphic Pnp mutants, predating the Arpaia knockout by six years and
    carrying residual enzyme activity rather than a null allele. They are curated as a separate
    model precisely because the negative result below is theirs and not the knockout's: a
    hypomorph failing to accumulate dGTP is a materially weaker negative than a null failing to,
    and attaching that claim to the field's principal model would overstate it.
  modeled_mechanisms:
  - target: Intracellular dGTP Pooling in Lymphoid Cells
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      This is the honest negative result, and it is the structural counterpart of the
      HUMAN_MODEL_MISMATCH discussion. In the B6-NPE and B6-NPF PNP-deficient mouse lines, the
      dGTP accumulation that the whole human mechanism is built on was not detectable in
      thymocytes, spleen leucocytes or erythrocytes, and there were no changes in purine or
      pyrimidine ribonucleotide pools. The lines instead showed a secondary deficiency of
      deoxyguanosine kinase, which would prevent the toxic phosphorylation step from running -
      so the mouse partly protects itself from the very lesion the model is meant to represent.
    limitations: >-
      This failure is line-specific rather than a property of murine PNP deficiency in general,
      and it does not overturn the mitochondrial hypothesis; it does mean that a murine failure
      to accumulate dGTP cannot be read as evidence about the human metabolic phenotype, and
      that dGTP-pooling claims must rest on human data.
    readouts:
    - name: dGTP concentration in thymocytes, spleen leucocytes and erythrocytes
      target: Intracellular dGTP Pooling in Lymphoid Cells
      direction: UNCHANGED
      interpretation: >-
        No detectable dGTP accumulation in the very compartments where the human mechanism
        predicts it - a genuine negative measurement, not an absence of testing.
      evidence:
      - reference: PMID:7918681
        reference_title: "Secondary loss of deoxyguanosine kinase activity in purine nucleoside phosphorylase deficient mice."
        supports: REFUTE
        evidence_source: MODEL_ORGANISM
        snippet: >-
          We found no evidence for dGTP accumulation in thymocytes or spleen leucocytes, < 1
          nmol/10(9) cells, nor in erythrocytes, < 0.05 nmol/10(9) cells, of the B6-NPE- or
          B6-NPF PNP-deficient mice strains.
        explanation: >-
          Directly reports the absence of dGTP accumulation in these mouse lines, which is why
          this link is recorded as FAILS_TO_RECAPITULATE.
    evidence:
    - reference: PMID:7918681
      reference_title: "Secondary loss of deoxyguanosine kinase activity in purine nucleoside phosphorylase deficient mice."
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We found no evidence for dGTP accumulation in thymocytes or spleen leucocytes, < 1
        nmol/10(9) cells, nor in erythrocytes, < 0.05 nmol/10(9) cells, of the B6-NPE- or
        B6-NPF PNP-deficient mice strains.
      explanation: >-
        The substantive negative finding required to justify a FAILS_TO_RECAPITULATE link.
    - reference: PMID:7918681
      reference_title: "Secondary loss of deoxyguanosine kinase activity in purine nucleoside phosphorylase deficient mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Fractionation of erythrocyte and liver lysates from the F mutation and the background
        strain, C57BL/6J, by anion exchange chromatography confirmed the secondary deficiency of
        deoxyguanosine kinase
      explanation: >-
        Identifies the secondary deoxyguanosine kinase deficiency that explains why these lines
        fail to accumulate dGTP - the mechanism of the model's failure, not merely its fact.

biochemical:
- name: Serum uric acid
  notes: >-
    Uric acid is the end product of the pathway PNP feeds, so it falls when the enzyme is
    absent. Together with lymphopenia it is the cheapest available diagnostic signal, and a low
    urate in a lymphopenic infant should prompt the specific enzyme assay. It is not perfectly
    sensitive: patients with partial deficiency had entirely normal serum urate.
  evidence:
  - reference: PMID:33061764
    reference_title: >-
      Recurrent infections, neurologic signs, low serum uric acid levels, and lymphopenia in
      childhood: Purine nucleoside phosphorylase deficiency, an emergency for infants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Absolute lymphocyte counts and serum uric acid levels were very low, and serum
      immunoglobulin levels were normal or slightly lower in all cases.
    explanation: >-
      Documents markedly low serum uric acid in all four cases of a confirmed series.
  - reference: PMID:32695102
    reference_title: >-
      Partial Purine Nucleoside Phosphorylase Deficiency Helps Determine Minimal Activity
      Required for Immune and Neurological Development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All siblings had normal blood uric acid and increased PNP substrates in the urine.
    explanation: >-
      Bounds the marker: normal urate in partial deficiency, so a normal value does not exclude
      the diagnosis. Recorded as PARTIAL for that reason.

- name: Urinary purine nucleosides
  notes: >-
    Inosine, deoxyinosine, guanosine and deoxyguanosine accumulate behind the enzymatic block
    and are excreted. This is the more sensitive half of the biochemical pair: it remained
    abnormal in partial-deficiency patients whose serum urate was normal.
  evidence:
  - reference: PMID:32695102
    reference_title: >-
      Partial Purine Nucleoside Phosphorylase Deficiency Helps Determine Minimal Activity
      Required for Immune and Neurological Development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All siblings had normal blood uric acid and increased PNP substrates in the urine.
    explanation: >-
      Shows urinary substrate elevation persisting when serum urate is normal, establishing it
      as the more sensitive marker.
  - reference: PMID:24767876
    reference_title: >-
      Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using
      tandem mass spectrometry on dried blood spots.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      caused by a enzyme defect leading to the accumulation of inosine, 2'-deoxy-inosine
      (dIno), guanosine, and 2'-deoxy-guanosine (dGuo) in all cells, especially lymphocytes
    explanation: >-
      Names the four accumulating substrates measured in this profile.

discussions:
- discussion_id: pnp-neurological-mechanism
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#CNS Purine Nucleotide Imbalance
  - pathophysiology#Neurological Dysfunction
  prompt: >-
    What causes the neurological disease in PNP deficiency? About two thirds of patients have
    spasticity, developmental delay or intellectual disability, and about a quarter present
    neurologically rather than with infection, yet no established mechanism links the
    enzymatic defect to neuronal dysfunction. The only mechanistic proposal in the literature
    - that depressed GTP levels may correlate with neurologic dysfunction - is offered as a
    possible correlation rather than a demonstrated pathway.
  rationale: >-
    Three observations make this a real gap rather than a missing citation. The neurological
    arm dissociates from the immunological one: patients are described with full
    immunodeficiency and autoimmunity but no neurological impairment. It is not corrected by
    the treatment that cures the immunodeficiency, since transplantation halts progression but
    does not reverse established disease. And the partial-deficiency siblings, with 8-11%
    residual activity, had entirely normal neurological development, which implies a threshold
    effect but says nothing about the mechanism below it. The clinical stake is direct: if the
    neurological injury is a prenatal or early-postnatal process, then newborn screening and
    very early transplantation would be the intervention, whereas if it is an ongoing
    metabolic toxicity then enzyme- or substrate-directed therapy able to cross the
    blood-brain barrier would be needed, since donor haematopoietic cells largely do not.
  evidence:
  - reference: PMID:1931007
    reference_title: Purine nucleoside phosphorylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Depressed GTP levels may correlate with neurologic dysfunction.
    explanation: >-
      The sole mechanistic proposal available, stated by the source itself only as a possible
      correlation - which is the gap.
  - reference: PMID:32695102
    reference_title: >-
      Partial Purine Nucleoside Phosphorylase Deficiency Helps Determine Minimal Activity
      Required for Immune and Neurological Development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All siblings had typical (normal) neurological development.
    explanation: >-
      Partial deficiency with 8-11% residual activity spared neurological development entirely,
      establishing a threshold without explaining the mechanism operating below it.
  proposed_experiments:
  - experiment_id: pnp-cns-purine-timing
    name: CSF purine profiling and neuroimaging across the PNP activity range
    description: >-
      Measure CSF purine nucleoside and nucleotide profiles alongside serial neuroimaging in
      patients spanning the full range of residual PNP activity, including pre- and
      post-transplant timepoints, to establish whether CNS purine imbalance tracks neurological
      severity, whether it is corrected by transplantation, and at what developmental stage the
      injury is established.
    readouts:
    - name: CSF purine metabolite levels versus neurological severity and PNP activity
      target: pathophysiology#CNS Purine Nucleotide Imbalance
    would_support:
    - pathophysiology#CNS Purine Nucleotide Imbalance
    - pathophysiology#Neurological Dysfunction

- discussion_id: pnp-dual-checkpoint-human-validation
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Unrestrained TLR7 Signalling by Guanosine Nucleoside Ligands
  - pathophysiology#SAMHD1-Dependent Synthetic Lethality in Developing T Cells
  prompt: >-
    The dual-checkpoint model - a SAMHD1-dependent synthetic lethality in developing T cells
    and a TLR7-ligand checkpoint in B cells and macrophages - elegantly explains why one
    metabolic gene produces both immunodeficiency and autoimmunity. It rests on mouse and
    cellular experiments. Do both checkpoints operate in human PNP deficiency, and does the
    TLR7 arm account for the autoimmunity seen in roughly a third of patients?
  rationale: >-
    Evidence for this model exists and is mechanistically strong, so the open question is
    translational validity rather than absence of data - which is what makes this a
    HUMAN_MODEL_MISMATCH rather than a knowledge gap. It matters for two reasons. If the human
    autoimmunity is TLR7-driven, then TLR7-directed or nucleoside-lowering therapy is a
    rational adjunct in patients awaiting transplant, whereas conventional immunosuppression
    in a patient who is already immunodeficient is an unattractive option. And if the T-cell
    arm genuinely depends on deoxycytidine kinase and is antagonised by microenvironmental
    deoxycytidine, that is a pharmacologically approachable dependency rather than an
    inevitability of the enzyme defect.
  evidence:
  - reference: PMID:35653193
    reference_title: >-
      Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell
      immunodeficiency and TLR7-associated autoimmunity.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      PNP insufficiency in humans is paradoxically associated with both immunodeficiency and
      autoimmunity, but the mechanistic basis for these outcomes is incompletely understood.
    explanation: >-
      The paper's own framing states that the human mechanistic basis is incompletely
      understood, which is precisely the mismatch this discussion records. Evidence source is
      MODEL_ORGANISM as the resolving experiments are murine and cellular.
  - reference: PMID:35968787
    reference_title: 'Immunodeficiency and autoimmunity: companions not opposites.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In this issue of the JCI, Abt and colleagues report on purine nucleoside phosphorylase
      (PNP) deficiency, exploring the basis for the autoimmune complications that develop in
      this particular form of T cell immune deficiency and assigning a key role for
      overactivation of TLR7.
    explanation: >-
      Independent commentary confirming the TLR7 attribution and its significance. Evidence
      source is OTHER as this is an editorial commentary rather than primary data.
  proposed_experiments:
  - experiment_id: pnp-human-tlr7-checkpoint
    name: TLR7 pathway activity in human PNP-deficient B cells and macrophages
    description: >-
      In patients with PNP deficiency, measure TLR7 pathway activation and interferon
      signatures in primary B cells and monocyte-derived macrophages, correlate with
      (deoxy)guanosine nucleoside levels and with the presence of autoimmune manifestations,
      and test whether ex vivo TLR7 blockade or nucleoside depletion normalises the signature.
    readouts:
    - name: TLR7 pathway activation versus nucleoside levels and autoimmune status
      target: pathophysiology#Unrestrained TLR7 Signalling by Guanosine Nucleoside Ligands
    would_support:
    - pathophysiology#Unrestrained TLR7 Signalling by Guanosine Nucleoside Ligands

notes: >-
  Module conformance: none declared. `metabolic_intoxication_decompensation` is the nearest
  candidate and does not fit - that module models acute decompensation crises (metabolic
  acidosis, hyperammonemia, hypoglycemia) unmasked by catabolic stress, whereas PNP deficiency
  produces chronic substrate accumulation with progressive cell loss and no acute
  decompensation phenotype. `lysosomal_substrate_accumulation` is also inapplicable: the
  accumulating substrate is cytosolic and mitochondrial, not lysosomal, and the toxicity is
  nucleotide-pool distortion rather than storage. A future "nucleotide salvage toxicity"
  module covering PNP and adenosine deaminase deficiency together would be a natural fit,
  since ADA deficiency runs the same architecture with dATP in place of dGTP acting on the
  same ribonucleotide reductase target; the attachment point would be the dGTP-pooling node.

  Frequency discipline: two phenotypes carry bands, both taken from explicit proportions in a
  33-patient literature review - neurological disease at two thirds and autoimmunity at one
  third, which fall at the upper and lower ends of FREQUENT (30-79%) respectively. All other
  phenotypes are left unbanded because the available sources are case series of three or four
  patients, which cannot support a population proportion.

  Evidence-source balance: the two mechanism nodes explaining the immunodeficiency/autoimmunity
  paradox rest on murine and cellular work and are tagged MODEL_ORGANISM throughout, with the
  translational question recorded as an explicit HUMAN_MODEL_MISMATCH rather than being
  smoothed into the human narrative.

📚

References & Deep Research

Deep Research

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 12 citations 2026-08-19T23:23:17.034156

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Purine nucleoside phosphorylase deficiency
MONDO ID: (if available)
Category: Inborn Error of Metabolism

Research Objectives

Please provide a comprehensive research report on Purine nucleoside phosphorylase deficiency covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Purine nucleoside phosphorylase deficiency: comprehensive disease-characteristics report

Scope and evidence note. This report integrates disease-level resources, recent reviews, human case-series evidence, and mechanistic mouse/in-vitro studies. Because PNP deficiency is exceptionally rare, many estimates derive from aggregated published cases rather than population registries. Exact variant frequencies, penetrance estimates, quality-of-life scores, and disease-specific survival curves remain unavailable. The most informative recent sources retrieved were Camici et al. (published June 2023; DOI 10.3390/metabo13070787) and Abt et al. (published August 2022; JCI 132:e160852; DOI 10.1172/JCI160852). (camici2023inbornerrorsof pages 24-26, abt2022purinenucleosidephosphorylase pages 1-2)

Executive summary

Purine nucleoside phosphorylase (PNP) deficiency is an autosomal-recessive inborn error of purine metabolism and inborn error of immunity caused by biallelic loss-of-function variants in PNP. Failure to catabolize inosine-, guanosine-, and deoxyguanosine-related substrates causes nucleoside accumulation, intracellular dGTP excess, nucleotide-pool imbalance, and selective injury to developing T cells. Patients consequently develop severe T-cell lymphopenia/combined immunodeficiency, recurrent or opportunistic infection, neurologic impairment, and paradoxical autoimmunity. Neurologic manifestations occur in approximately two-thirds and autoimmune disease in approximately one-third of reported patients; onset is usually between 4 months and 6 years, but expression is highly variable. (camici2023inbornerrorsof pages 24-26)

Biochemical diagnosis rests on elevated inosine/guanosine—and often deoxyguanosine—in blood or urine, low uric acid, and markedly reduced PNP enzyme activity; molecular confirmation requires identifying pathogenic variants on both alleles. Allogeneic hematopoietic stem-cell transplantation (HSCT) is the established definitive treatment for immune disease. It can restore immunity and prevent further infections, but pre-existing neurologic deficits may persist, making presymptomatic diagnosis and early transplantation important. (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)

domain	high-confidence annotation	suggested ontology/identifier	evidence caveat
Disease entity	Purine nucleoside phosphorylase deficiency; rare inborn error of purine metabolism with immunodeficiency and neurologic/autoimmune manifestations	MONDO:0013171; category suggestion: inborn error of metabolism / inborn error of immunity (OpenTargets Search: purine nucleoside phosphorylase deficiency-PNP, camici2023inbornerrorsof pages 24-26)	MONDO supported by OpenTargets context; some classifications differ between metabolic and immunologic taxonomies
Synonyms	PNP deficiency; purine nucleoside phosphorylase defect; PNP-deficient SCID/combined immunodeficiency	MeSH/OMIM/Orphanet mapping suggestion only; exact IDs not confirmed here (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)	Exact synonym lists and external IDs should be verified in OMIM/Orphanet/MeSH
Causal gene	Biallelic pathogenic variants in PNP cause disease	PNP; Ensembl: ENSG00000198805; HGNC symbol: PNP (OpenTargets Search: purine nucleoside phosphorylase deficiency-PNP, camici2023inbornerrorsof pages 24-26)	Gene-disease link is high confidence; transcript-level reference not specified here
Inheritance	Autosomal recessive loss-of-function disorder	Inheritance suggestion: HP term for autosomal recessive inheritance; gene mechanism suggestion: loss of function (camici2023inbornerrorsof pages 24-26, abt2022purinenucleosidephosphorylase pages 1-2)	Exact HPO inheritance ID not supplied to avoid invention
Core biochemical defect	Deficiency of purine nucleoside phosphorylase activity impairs phosphorolysis of inosine/guanosine and deoxy forms, causing toxic purine metabolite accumulation	GO suggestion: purine nucleoside phosphorylase activity; Reactome/KEGG suggestion: purine metabolism / salvage pathway (camici2023inbornerrorsof pages 24-26, shanta2020purinenucleosidephosphorylase pages 1-2)	Exact GO/Reactome IDs not confirmed here
Key metabolites/biomarkers	Elevated inosine and guanosine in blood/urine; elevated guanosine and deoxyguanosine reported; reduced uric acid	CHEBI suggestions: inosine, guanosine, deoxyguanosine, uric acid (camici2023inbornerrorsof pages 24-26, abt2022purinenucleosidephosphorylase pages 1-2)	Exact CHEBI IDs not provided; biomarker patterns may vary by assay and timing
Mechanistic toxic intermediate	Deoxyguanosine is phosphorylated to dGTP, producing dNTP imbalance and ribonucleotide reductase inhibition with lymphocyte toxicity	GO suggestions: apoptotic process, mitochondrial apoptotic pathway, nucleotide metabolic process (camici2023inbornerrorsof pages 24-26, shanta2020purinenucleosidephosphorylase pages 1-2)	dGTP mechanism is strongly supported, but exact downstream pathways vary by model/system
Immune phenotype	Profound T-cell lymphopenia/combined immunodeficiency with recurrent severe infections; B-cell compartment may be less affected than T cells	HPO suggestions: T-cell lymphopenia, combined immunodeficiency, recurrent infections, immunodeficiency; NCIT suggestion: Severe Combined Immunodeficiency (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46, shanta2020purinenucleosidephosphorylase pages 1-2)	Exact HPO/NCIT IDs not confirmed; some patients are described as SCID, others as CID/leaky SCID
Neurologic phenotype	Neurologic manifestations reported in approximately two-thirds of cases; includes ataxia, developmental delay, intellectual disability, spasticity/paraplegia in some reports	HPO suggestions: ataxia, developmental delay, intellectual disability, spastic paraplegia (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)	Frequency estimate is from review-level synthesis; patient-level prevalence varies
Autoimmune phenotype	Autoimmune manifestations reported in approximately one-third of cases; examples include immune thrombocytopenia, thyroiditis, lupus/SLE-like disease, autoimmune hemolytic anemia, inflammatory arthritis/MAS-like presentations	HPO suggestions: autoimmune thrombocytopenia, thyroiditis, systemic lupus erythematosus, autoimmune hemolytic anemia; disease feature suggestion: autoimmunity (camici2023inbornerrorsof pages 24-26, abt2022purinenucleosidephosphorylase pages 1-2, camici2023inbornerrorsof pages 45-46)	Frequency estimate is approximate; specific autoimmune diagnoses are heterogeneous and often case-based
Age at onset / course	Typically presents from about 4 months to 6 years; severity is variable	HPO suggestions: infantile onset / childhood onset (camici2023inbornerrorsof pages 24-26)	Exact onset distribution is not well quantified due to rarity
Major affected cells	Thymocytes/T-cell progenitors are especially vulnerable; B lymphocytes and macrophages are implicated in autoimmunity/TLR7 signaling	CL suggestions: thymocyte, T-cell progenitor, T lymphocyte, B lymphocyte, macrophage (abt2022purinenucleosidephosphorylase pages 1-2, shanta2020purinenucleosidephosphorylase pages 1-2)	Exact CL IDs not confirmed; evidence spans human, mouse, and mechanistic systems
Major anatomy	Primary involvement of immune system, especially thymus and peripheral lymphoid tissues; nervous system involvement is common	UBERON suggestions: thymus, spleen, lymph node, peripheral blood, brain/nervous system (camici2023inbornerrorsof pages 24-26, abt2022purinenucleosidephosphorylase pages 1-2)	Exact UBERON IDs not confirmed; organ involvement is inferred from phenotype and model data
Upstream/downstream pathway annotation	Upstream: PNP loss in purine salvage/catabolism. Downstream: purine nucleoside accumulation, dGTP excess, mitochondrial apoptosis, T-cell depletion; separate checkpoint links guanosine metabolites to TLR7-associated autoimmunity	GO suggestions: purine nucleoside metabolic process, intrinsic apoptotic signaling pathway, toll-like receptor signaling pathway, lymphocyte differentiation (abt2022purinenucleosidephosphorylase pages 1-2, shanta2020purinenucleosidephosphorylase pages 1-2)	TLR7 checkpoint evidence is particularly strengthened by 2022 mechanistic work and model systems
Diagnosis	Diagnostic workup includes enzyme assay, metabolite profiling, and molecular testing of PNP; dried-blood-spot tandem mass spectrometry has been reported for early diagnosis/newborn detection	Diagnostic test suggestion: PNP enzyme activity assay; metabolomics/MS-MS; single-gene or panel sequencing of PNP (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)	Exact assay thresholds and sensitivity/specificity not available in retrieved evidence
Screening	Newborn screening is feasible using DBS tandem mass spectrometry, but not universally routine	Screening program suggestion: newborn screening for SCID/purine disorders (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)	Implementation is jurisdiction-dependent; broad population performance metrics not available here
Definitive treatment	Hematopoietic stem cell transplantation (HSCT) is the only established curative therapy for immune reconstitution	NCIT suggestion: Hematopoietic Stem Cell Transplantation / Bone Marrow Transplantation (camici2023inbornerrorsof pages 24-26)	Strong consensus on immune benefit; exact NCIT code not confirmed
Treatment outcome caveat	HSCT generally restores immune function and reduces infections, but neurologic recovery is incomplete/variable	Outcome annotation suggestion: immune reconstitution; persistent neurodevelopmental impairment possible (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)	Disease-specific long-term survival percentages were not available in retrieved evidence
Residual activity / genotype-phenotype note	Near-normal immune and neurologic development may require roughly 8-11% residual PNP activity	Functional evidence annotation suggestion: residual enzyme activity modifier (camici2023inbornerrorsof pages 24-26)	Review-derived estimate; should be confirmed against original patient series before KB hard-coding
Model organism	PNP-deficient/PNP-knockout mice support thymic/T-cell toxicity mechanisms and autoimmune checkpoint biology but incompletely recapitulate human disease	Model suggestion: mouse Pnp knockout / deficient mouse (camici2023inbornerrorsof pages 24-26, abt2022purinenucleosidephosphorylase pages 1-2)	Mouse models show important limitations, including partial mismatch with human thymic/T-cell phenotype

Table: This table summarizes high-confidence, knowledge-base-ready annotations for purine nucleoside phosphorylase deficiency, including disease identity, gene, mechanism, phenotypes, diagnostics, and treatment. Ontology mappings are labeled as suggestions where exact identifiers were not confirmed in the available evidence.

1. Disease information

Definition and classification

PNP deficiency is both an inborn error of metabolism—specifically purine salvage/catabolism—and an inborn error of immunity, commonly classified clinically as combined immunodeficiency or SCID-like disease. Alternative names include PNP deficiency, purine nucleoside phosphorylase defect, PNP-deficient combined immunodeficiency, and PNP-deficient SCID. The historical description emphasized severe T-cell deficiency with relatively preserved B-cell numbers, although B-cell function and immune regulation can also be abnormal. (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)

Identifiers:

MONDO: MONDO:0013171, directly linked to PNP/ENSG00000198805 in Open Targets. (OpenTargets Search: purine nucleoside phosphorylase deficiency-PNP)
Gene: PNP; Ensembl ENSG00000198805. (OpenTargets Search: purine nucleoside phosphorylase deficiency-PNP)
OMIM: commonly catalogued as PNP gene 164050 and immunodeficiency due to PNP deficiency 613179; these numbers should be verified directly in OMIM before production ingestion.
Orphanet/MeSH: disease entries exist, but exact identifiers were not independently confirmed in the retrieved full-text evidence.
ICD-10/ICD-11: there is no widely used disease-specific billing code; cases are generally coded under combined/severe combined immunodeficiency or other specified disorders of purine metabolism.

The evidence is predominantly aggregated disease-level literature, supplemented by small cohorts and individual cases—not EHR-derived patient-level data.

2. Etiology, risk, and protective factors

The sole established primary cause is biallelic germline loss of PNP function. Inheritance is autosomal recessive: each sibling of two carrier parents has a 25% probability of being affected, 50% probability of being a carrier, and 25% probability of inheriting neither familial variant. PNP is the only high-confidence associated target in Open Targets for MONDO:0013171. (OpenTargets Search: purine nucleoside phosphorylase deficiency-PNP, camici2023inbornerrorsof pages 24-26)

Reported pathogenic alleles include missense, nonsense, frameshift, and splice-altering variants. Their common consequence is absent or severely reduced enzyme activity. No robust disease-wide genotype–phenotype relationship has been established. Residual activity is biologically important: review-level evidence suggests approximately 8–11% activity may permit near-normal immune and neurologic development. (camici2023inbornerrorsof pages 24-26)

No environmental, dietary, lifestyle, occupational, infectious, sex-specific, or polygenic factor is known to cause the disorder. Infections are consequences and clinical stressors, not etiologic agents. Consanguinity and an affected family history increase reproductive risk by increasing the probability that both parents carry the same rare allele. No validated protective allele, modifier gene, epigenetic signature, or gene–environment interaction is established. Avoiding infection may reduce morbidity but cannot prevent the biochemical disease.

3. Phenotypes

Immune and infectious manifestations

The central laboratory phenotype is progressive T-cell lymphopenia with profound T-cell dysfunction. Clinical manifestations include recurrent bacterial, viral, fungal, and opportunistic infections, chronic respiratory or gastrointestinal infection, and failure to thrive. Severity ranges from SCID in infancy to later-onset combined immunodeficiency. Suggested HPO annotations are Immunodeficiency, Combined immunodeficiency, T-cell lymphopenia, Recurrent respiratory infections, Opportunistic infection, Chronic diarrhea, and Failure to thrive. (camici2023inbornerrorsof pages 24-26, shanta2020purinenucleosidephosphorylase pages 1-2)

Neurologic and developmental manifestations

Approximately two-thirds of reported patients have neurologic disease, which can precede recognized infections. Manifestations include global developmental delay, intellectual disability, ataxia, hypotonia or spasticity, motor dysfunction, and occasionally spastic paraplegia. Severity and progression are variable; established injury may not reverse after HSCT. Suggested HPO terms include Global developmental delay, Intellectual disability, Ataxia, Muscular hypotonia, Spasticity, Spastic paraplegia, and Abnormality of gait. (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46, shanta2020purinenucleosidephosphorylase pages 3-4)

Autoimmunity, inflammation, and malignancy

Approximately one-third develop autoimmune manifestations, including immune thrombocytopenia, autoimmune hemolytic anemia, thyroiditis, lupus/SLE-like disease, inflammatory arthritis, and macrophage-activation-syndrome-like presentations. Lymphoma has been reported in late-onset disease. One mechanistically studied case showed IL-18 more than 400-fold elevated, with high CXCL9, supporting IFN-γ-linked hyperinflammation, but this is not a validated diagnostic biomarker. Suggested HPO terms include Autoimmunity, Thrombocytopenia, Autoimmune hemolytic anemia, Thyroiditis, and Systemic lupus erythematosus. (abt2022purinenucleosidephosphorylase pages 1-2, camici2023inbornerrorsof pages 45-46, shanta2020purinenucleosidephosphorylase pages 3-4)

No validated PNP-specific EQ-5D, SF-36, PROMIS, or other quality-of-life dataset was found. Nevertheless, recurrent hospitalization, infection precautions, neurodevelopmental disability, mobility impairment, and transplant morbidity substantially affect schooling, independence, caregiver burden, and well-being.

4. Genetic and molecular information

PNP encodes purine nucleoside phosphorylase, a cytosolic homotrimeric enzyme that catalyzes reversible phosphorolysis of inosine, guanosine, deoxyinosine, and deoxyguanosine to corresponding purine bases plus ribose-1-phosphate or deoxyribose-1-phosphate. Disease alleles act through loss of function, not gain of function or dominant-negative activity. (shanta2020purinenucleosidephosphorylase pages 1-2)

Variants are constitutionally germline and usually inherited from heterozygous parents. Variant interpretation should follow ACMG/AMP criteria using segregation, rarity in gnomAD, enzyme activity, biochemical phenotype, RNA evidence for splice variants, and functional assays. A comprehensive current ClinVar/gnomAD variant table could not be reconstructed from the retrieved documents; therefore, no individual HGVS allele or population frequency should be hard-coded without direct database verification.

No confirmed modifier gene, recurrent chromosomal rearrangement, somatic driver, disease-specific methylation signature, or chromatin abnormality is known. CMA, karyotyping, and FISH are consequently not first-line tests unless a broader syndromic or copy-number diagnosis is suspected.

5. Environmental and infectious information

There are no demonstrated toxin, radiation, pollution, diet, smoking, alcohol, exercise, or occupational causes. Dietary purine restriction is not an established disease-modifying treatment because cellular purines derive mainly from de novo synthesis and nucleic-acid turnover, with dietary intake contributing only marginally. (camici2023inbornerrorsof pages 24-26)

Pathogens do not cause PNP deficiency. They exploit the resulting T-cell defect and drive morbidity. Exposure reduction, safe food and water practices, household infection control, and rapid treatment of fever are tertiary-prevention measures rather than etiologic interventions.

6. Mechanism and pathophysiology

Causal chain

Upstream genetic lesion: biallelic PNP loss reduces phosphorolysis and recycling of purine nucleosides.
Metabolic block: inosine, guanosine, deoxyinosine, and especially deoxyguanosine accumulate; conversion toward hypoxanthine/guanine and ultimately uric acid falls.
T-cell-toxic branch: deoxyguanosine is phosphorylated by deoxycytidine kinase to dGTP, particularly in immature T cells, which have high kinase and relatively low dephosphorylating capacity.
Cellular injury: dGTP excess disturbs dNTP pools, inhibits ribonucleotide reductase, impairs DNA synthesis/repair, promotes DNA fragmentation and mitochondrial apoptosis.
Tissue phenotype: progressive thymocyte/T-cell-progenitor loss produces peripheral T-cell lymphopenia and infection susceptibility. (camici2023inbornerrorsof pages 24-26, shanta2020purinenucleosidephosphorylase pages 1-2)

A second checkpoint helps explain the apparent paradox of autoimmunity amid immunodeficiency. Mechanistic mouse and cellular work indicates that PNP restrains guanosine/deoxyguanosine-dependent TLR7 signaling in B cells and macrophages. PNP loss can therefore combine T-cell depletion with excessive innate/B-cell nucleic-acid sensing and lupus-like inflammation. Abt et al. summarize the phenotype as “profound T cell immunodeficiency and paradoxical autoimmunity.” (abt2022purinenucleosidephosphorylase pages 1-2)

Suggested GO biological-process terms include purine nucleoside metabolic process, purine-containing compound salvage, deoxyribonucleotide metabolic process, ribonucleotide reductase regulation, intrinsic apoptotic signaling pathway, T-cell differentiation, and Toll-like receptor 7 signaling pathway. Suggested cell types are thymocyte, T-cell progenitor, mature T lymphocyte, B lymphocyte, and macrophage. Exact GO and Cell Ontology identifiers should be validated before ingestion.

Molecular profiling

The clinically useful molecular signature is metabolomic: high inosine/guanosine/deoxyguanosine and low uric acid. No reproducible disease-specific transcriptomic, proteomic, lipidomic, single-cell, spatial-transcriptomic, or integrated multi-omics atlas was identified. Elevated IL-18/CXCL9 is hypothesis-generating rather than validated. (camici2023inbornerrorsof pages 24-26, shanta2020purinenucleosidephosphorylase pages 3-4)

7. Anatomical structures affected

The immune system is primary, especially thymus, thymocytes/T-cell progenitors, peripheral blood T cells, spleen, lymph nodes, and bone marrow/hematopoietic progenitors. The central nervous system is a major nonimmune target, expressed through developmental, motor, cerebellar, and pyramidal abnormalities. Respiratory and gastrointestinal tissues are secondarily injured by recurrent infection; spleen and blood lineages can be affected by immune dysregulation or cytopenias. (camici2023inbornerrorsof pages 24-26, abt2022purinenucleosidephosphorylase pages 1-2)

Suggested UBERON mappings are thymus, bone marrow, spleen, lymph node, blood, brain, cerebellum, and spinal cord. Suggested GO cellular compartments include cytosol—the principal site of soluble PNP activity—and mitochondrion for downstream apoptotic signaling. Disease lateralization is not characteristic.

8. Temporal development and natural history

Typical recognized onset is 4 months to 6 years, although residual-function disease may present later. The course is chronic and generally progressive without immune reconstitution: toxic metabolites accumulate, thymic injury and lymphopenia worsen, infections recur, and neurologic or autoimmune manifestations emerge variably. PNP-knockout mice likewise have relatively preserved T-cell production at birth followed by progressive thymic injury, supporting an early therapeutic window. (camici2023inbornerrorsof pages 24-26)

There are no validated stages. A practical clinical sequence is: presymptomatic biochemical/genetic disease; early lymphopenia or developmental abnormality; recurrent infection/combined immunodeficiency; and advanced multisystem disease with neurologic disability, autoimmunity, chronic infection, or malignancy. Remission without treatment is not expected. HSCT can induce durable immune remission but does not reliably reverse established neurologic damage. (camici2023inbornerrorsof pages 45-46, camici2023inbornerrorsof pages 24-26)

9. Inheritance and population

PNP deficiency is autosomal recessive, affects both sexes, and is worldwide. Consanguineous populations and founder families may show local enrichment, but no robust global prevalence, annual incidence, carrier frequency, ethnic distribution, or sex ratio is established. The published literature is too sparse and referral-biased for reliable cases-per-100,000 estimates.

Penetrance of two severe loss-of-function alleles appears high, but expressivity is variable and depends partly on residual activity. Genetic anticipation is not expected. Germline mosaicism has not emerged as a characteristic mechanism, although low-level parental mosaicism is theoretically possible. Carriers are generally asymptomatic because one functional allele supplies adequate activity.

10. Diagnostics and screening

Recommended diagnostic workflow

Suspect PNP deficiency in a child with T-cell lymphopenia/CID plus developmental delay, ataxia/spasticity, autoimmunity, low uric acid, or consanguinity.
Perform CBC/differential, absolute lymphocyte count, CD3/CD4/CD8/CD19/NK enumeration, immunoglobulins, vaccine responses, lymphocyte proliferation, infection testing, and T-cell receptor excision circles where available.
Measure plasma/serum and urine purines by HPLC or LC-MS/MS. The characteristic pattern is elevated inosine and guanosine/deoxyguanosine with low serum/urine uric acid.
Confirm low or absent PNP enzyme activity in erythrocytes, leukocytes, or another validated specimen.
Confirm biallelic pathogenic/likely pathogenic PNP variants by sequencing with deletion/duplication analysis. (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)

A single-gene assay or comprehensive SCID/CID panel is appropriate when the phenotype is recognizable. WES/WGS is useful in atypical cases or when panel testing is negative, particularly for deep-intronic or structural variants. CMA, karyotype, FISH, mitochondrial sequencing, and repeat-expansion assays are not routine PNP tests.

Differential diagnosis

Major alternatives include ADA deficiency, IL2RG/JAK3/IL7R-related SCID, RAG1/RAG2/DCLRE1C defects, AK2-related reticular dysgenesis, DOCK8 deficiency, ataxia-telangiectasia, and other metabolic neurologic disorders. PNP deficiency is distinguished by elevated guanosine/deoxyguanosine and inosine, low uric acid, deficient PNP activity, and biallelic PNP variants. Autoimmunity can misleadingly suggest primary rheumatic disease; recurrent infection or lymphopenia should prompt immunologic testing. (camici2023inbornerrorsof pages 45-46, shanta2020purinenucleosidephosphorylase pages 3-4)

Screening

Dried-blood-spot tandem mass spectrometry can detect the purine signature and has been proposed for newborn diagnosis, but it is not universally incorporated into routine newborn panels. Standard TREC-based SCID screening may identify marked T-cell lymphopenia, although milder or evolving disease could be missed. Cascade testing of siblings and carrier testing of relatives are strongly indicated. (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)

11. Outcome and prognosis

Untreated severe disease carries high risks of life-threatening infection, progressive neurologic disability, autoimmunity, cytopenias, and occasional lymphoma. SCID broadly is fatal without immune reconstitution, but a reliable PNP-specific untreated median survival or 5-/10-year survival rate was not available. (abt2022purinenucleosidephosphorylase pages 1-2)

HSCT can restore immune function and produce infection-free survival, but neurodevelopmental outcome is heterogeneous; persistent delay despite successful transplantation is documented. Favorable prognostic features plausibly include early diagnosis, transplantation before severe infection or neurologic injury, good donor match, low pretransplant organ burden, and some residual enzyme activity. These have not been combined into a validated PNP-specific prognostic model. (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)

12. Treatment

Definitive therapy

Allogeneic HSCT is the established curative treatment for the hematopoietic/immune defect. Donor selection, conditioning intensity, graft source, and graft-versus-host-disease prophylaxis should be individualized at an experienced primary-immunodeficiency transplant center. Immune reconstitution and freedom from recurrent infection are expected goals; neurologic recovery cannot be assured. Suggested NCIt interventions are Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, and Allogeneic Stem Cell Transplantation. (camici2023inbornerrorsof pages 24-26)

Supportive management

Before reconstitution, management generally follows SCID/CID principles: antimicrobial prophylaxis, aggressive organism-directed treatment, immunoglobulin replacement when humoral function is inadequate, CMV-safe/irradiated blood products, nutritional support, and physical, occupational, speech, and neurodevelopmental therapies. Live vaccines should be avoided in significantly immunodeficient patients. Autoimmune disease requires specialist-directed immunomodulation balanced against infection risk.

No drug corrects inherited PNP deficiency. Forodesine and ulodesine are PNP inhibitors, studied to suppress or modulate immune cells in cancer, psoriasis, or gout; they mechanistically mimic aspects of PNP loss and are not treatments for this deficiency. (shanta2020purinenucleosidephosphorylase pages 1-2)

Gene replacement, gene editing, mRNA/RNA therapy, and enzyme/protein replacement remain experimental concepts. In-vitro delivery of PNP protein and retroviral correction models demonstrate feasibility, but no approved PNP-specific product was identified. No established pharmacogenomic guideline exists.

13. Prevention

Primary prevention by lifestyle or vaccination is impossible because the disease is inherited. Effective reproductive prevention includes genetic counseling, parental carrier confirmation, cascade testing, prenatal diagnosis, and preimplantation genetic testing for a known familial genotype.

Secondary prevention consists of newborn/TREC or metabolite screening where available, prompt evaluation of an affected sibling, and early HSCT before infection and neurologic damage. Tertiary prevention includes antimicrobial prophylaxis, immunoglobulin replacement when indicated, avoidance of live vaccines and unsafe blood products, rapid infection treatment, neurologic rehabilitation, and malignancy/autoimmunity surveillance. (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)

Inactivated vaccines may be ineffective before immune reconstitution; vaccination after HSCT should follow transplant-team schedules. Household contacts should be appropriately immunized, with live-vaccine exposure precautions determined by the immunology team.

14. Other species and naturally occurring disease

No well-established naturally occurring veterinary analogue in a specific companion-animal breed was identified. PNP orthologues are widely conserved among vertebrates, but experimental knockout/deficient animals should not be confused with spontaneous natural disease. There is no infectious transmission, zoonotic potential, or cross-species contagion.

15. Model organisms and experimental systems

Mouse Pnp-deficiency/knockout models reproduce toxic purine accumulation and progressive thymocyte abnormalities and have been used to investigate T-cell development, dGTP toxicity, and TLR7-associated autoimmunity. Some models develop pancytopenia, massive splenomegaly, and premature death. However, they incompletely reproduce human disease: one model had only minor thymic defects and largely preserved peripheral T-cell compartments, so therapeutic effects cannot be extrapolated without human confirmation. (camici2023inbornerrorsof pages 24-26, abt2022purinenucleosidephosphorylase pages 1-2)

Cellular systems include PNP-deficient lymphocytes, thymocyte cultures, gene-corrected T-cell lines, and pharmacologic PNP inhibition. They are useful for enzyme kinetics, metabolite flux, synthetic interactions involving deoxycytidine kinase/SAMHD1, apoptosis, and gene-replacement proof of concept, but cannot model neurodevelopment or whole-body immune regulation.

Recent developments and current implementation

2023 metabolic synthesis: Camici et al. consolidated the estimate that neurologic disease affects about two-thirds and autoimmunity about one-third, highlighted DBS-MS screening, and emphasized that HSCT restores immunity while neurologic benefit remains uncertain. The authors’ abstract states that purine dysmetabolism can be accompanied by “devastating symptoms” and that some manifestations still have “no explanation or therapy.” (camici2023inbornerrorsof pages 24-26)
Mechanistic advance: Abt et al. established dual PNP-dependent checkpoints—dGTP-associated T-cell toxicity and guanosine/TLR7-associated immune activation—providing a coherent explanation for immunodeficiency coexisting with autoimmunity. (abt2022purinenucleosidephosphorylase pages 1-2)
Real-world diagnostics: HPLC/LC-MS/MS metabolite testing, enzyme assays, immunophenotyping, and molecular sequencing are clinically implementable; DBS tandem-MS offers a potential presymptomatic screening route. (camici2023inbornerrorsof pages 24-26, camici2023inbornerrorsof pages 45-46)
Clinical research: A ClinicalTrials.gov search identified the recruiting NIH observational natural-history protocol NCT06092346, designed to study clinical, genomic, pharmacologic, laboratory, and dietary determinants across purine and pyrimidine disorders. No active PNP-specific interventional gene- or enzyme-therapy trial was identified in the retrieved registry results.

Evidence gaps and curation cautions

The field lacks a prospective international registry with standardized genotype, residual enzyme activity, infection burden, neurodevelopmental testing, transplant regimen, and long-term outcome. Published frequencies are vulnerable to survival and ascertainment bias. Exact individual variant classifications and gnomAD frequencies require direct current ClinVar/gnomAD review. Disease-specific QoL instruments, validated prognostic biomarkers, controlled treatment-response rates, and single-cell/spatial multi-omics datasets are absent. Ontology labels in the table are therefore proposed mappings rather than definitive identifier assignments unless explicitly stated.

References

(camici2023inbornerrorsof pages 24-26): Marcella Camici, Mercedes Garcia-Gil, Simone Allegrini, Rossana Pesi, Giulia Bernardini, Vanna Micheli, and Maria Grazia Tozzi. Inborn errors of purine salvage and catabolism. Metabolites, 13:787, Jun 2023. URL: https://doi.org/10.3390/metabo13070787, doi:10.3390/metabo13070787. This article has 27 citations.
(abt2022purinenucleosidephosphorylase pages 1-2): Evan R. Abt, Khalid Rashid, Thuc M. Le, Suwen Li, Hailey R. Lee, Vincent Lok, Luyi Li, Amanda L. Creech, Amanda N. Labora, Hanna K. Mandl, Alex K. Lam, Arthur Cho, Valerie Rezek, Nanping Wu, Gabriel Abril-Rodriguez, Ethan W. Rosser, Steven D. Mittelman, Willy Hugo, Thomas Mehrling, Shanta Bantia, Antoni Ribas, Timothy R. Donahue, Gay M. Crooks, Ting-Ting Wu, and Caius G. Radu. Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent t cell immunodeficiency and tlr7-associated autoimmunity. Journal of Clinical Investigation, Aug 2022. URL: https://doi.org/10.1172/jci160852, doi:10.1172/jci160852. This article has 45 citations and is from a highest quality peer-reviewed journal.
(camici2023inbornerrorsof pages 45-46): Marcella Camici, Mercedes Garcia-Gil, Simone Allegrini, Rossana Pesi, Giulia Bernardini, Vanna Micheli, and Maria Grazia Tozzi. Inborn errors of purine salvage and catabolism. Metabolites, 13:787, Jun 2023. URL: https://doi.org/10.3390/metabo13070787, doi:10.3390/metabo13070787. This article has 27 citations.
(OpenTargets Search: purine nucleoside phosphorylase deficiency-PNP): Open Targets Query (purine nucleoside phosphorylase deficiency-PNP, 8 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(shanta2020purinenucleosidephosphorylase pages 1-2): Bantia Shanta. Purine nucleoside phosphorylase inhibitors as novel immuno-oncology agent and vaccine adjuvant. International Journal of Immunology and Immunotherapy, Apr 2020. URL: https://doi.org/10.23937/2378-3672/1410043, doi:10.23937/2378-3672/1410043. This article has 12 citations.
(shanta2020purinenucleosidephosphorylase pages 3-4): Bantia Shanta. Purine nucleoside phosphorylase inhibitors as novel immuno-oncology agent and vaccine adjuvant. International Journal of Immunology and Immunotherapy, Apr 2020. URL: https://doi.org/10.23937/2378-3672/1410043, doi:10.23937/2378-3672/1410043. This article has 12 citations.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	4
Resolved	4
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	4
On topic	0
Off topic	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Clinical Trials

Animal Models

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Purine nucleoside phosphorylase deficiency: comprehensive disease-characteristics report

Executive summary

1. Disease information

Definition and classification

2. Etiology, risk, and protective factors

3. Phenotypes

Immune and infectious manifestations

Neurologic and developmental manifestations

Autoimmunity, inflammation, and malignancy

4. Genetic and molecular information

5. Environmental and infectious information

6. Mechanism and pathophysiology

Causal chain

Molecular profiling

7. Anatomical structures affected

8. Temporal development and natural history

9. Inheritance and population

10. Diagnostics and screening

Recommended diagnostic workflow

Differential diagnosis

Screening

11. Outcome and prognosis

12. Treatment

Definitive therapy

Supportive management

13. Prevention

14. Other species and naturally occurring disease

15. Model organisms and experimental systems

Recent developments and current implementation

Evidence gaps and curation cautions

Artifacts

Reference Validation